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Abbreviations  
ACTH: adrenocorticotrophic hormone 
PPNAD: primary pigmented nodular adrenocortical disease 
BMAH: bilateral macronodular adrenal hyperplasia 
 cAMP: cyclic adenosine monophosphate 
MC2R: melanocortin 2 receptor 
PKA: protein kinase A 
CREB: cAMP response element binding protein 
PDE: phosphodiesterase 
 
  
6
Di Dalmazi - Doctoral Thesis 
 
 
Publication list  
First publication 
Title: Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal 
Cushing’s syndrome: a European multicentric study. 
Authors: Guido Di Dalmazi, Caroline Kisker, Davide Calebiro, Massimo Mannelli, Letizia Canu, Giorgio 
Arnaldi, Marcus Quinkler, Nada Rayes, Antoine Tabarin, Marie Laure Jullié, Franco Mantero, Beatrice 
Rubin, Jens Waldmann, Detlef K Bartsch, Renato Pasquali, Martin Lohse, Bruno Allolio, Martin 
Fassnacht, Felix Beuschlein, Martin Reincke.  
Journal/Year/Issue/Pages: The Journal of Clinical Endocrinology and Metabolism, 2014; 99(10): 
E2093–E2100. doi: 10.1210/jc.2014-2152. 
 
Second publication 
Title: Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA 
p.Leu206Arg Mutation 
Authors: Ronchi CL*, Di Dalmazi G*, Faillot S*, Sbiera S, Assié G, Weigand I, Calebiro D, Schwarzmayr 
T, Appenzeller S, Rubin B, Waldmann J, Scaroni C, Bartsch DK, Mantero F, Mannelli M, Kastelan D, 
Chiodini I, Bertherat J, Reincke M, Strom TM, Fassnacht M, Beuschlein F; European Network for the 
Study of Adrenocortical Tumors (ENSAT).  
Journal/Year/Issue/Pages: The Journal of Clinical Endocrinology and Metabolism, 2016; 101(9): 3526-
3538. doi: 10.1210/jc.2016-1586.  
*Authors contributed equally to the work 
7
Di Dalmazi - Doctoral Thesis 
 
 
Confirmation of co-authors  
All authors listed in the publications gave their contribution to achieve the results of the two studies. 
A confirmation with the signature of each co-author is submitted as a separate file. 
  
8
Di Dalmazi - Doctoral Thesis 
 
 
Introduction 
Cushing's syndrome is a pathological condition characterized by excessive cortisol production by the 
adrenals. The endogenous hypercortisolism can be caused by increased secretion of ACTH or can be 
the result of an autonomous activity of the adrenal glands. The ACTH-dependent form is the most 
frequent cause of Cushing´s syndrome, accounting for almost 70% of all cases of endogenous 
hypercortisolism. The corticotropin–dependent hypercortisolism is caused by excessive and 
autonomous secretion of ACTH by the pituitary gland (Cushing´s disease), mostly due to a pituitary 
adenoma, or by ectopic production of 
ACTH in up to 10% of all cases of 
endogenous hypercortisolism (ectopic 
Cushing´s syndrome). ACTH-independent 
Cushing's syndrome, the most frequent 
subtype, is due to unilateral 
adrenocortical adenomas and carcinomas 
(18-20%). Bilateral adrenal hyperplasia 
(primary pigmented nodular 
adrenocortical disease – PPNAD - and 
bilateral macronodular adrenal hyperplasia - BMAH) are rare causes (< 1%). The classification of 
endogenous hypercortisolism is summarized in Figure 1A. The clinical picture of Cushing´s syndrome 
is characterized by severe comorbidities and adverse events, which are related to the effects of the 
prolonged excessive cortisol production. Indeed, the deleterious consequences of cortisol 
hypersecretion involve many organ systems, considering that the glucocorticoid receptor is 
widespread expressed among almost all tissues. The classic clinical stigmata of a patient affected by 
Cushing´s syndrome are centripetal obesity, proximal muscle weakness, moon face, striae rubrae, and 
Figure 1. Classification of endogenous hypercortisolism (A) and 
typical clinical features of Cushing´s syndrome (B).  
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hirsutism (1), as depicted in Figure 1B. Moreover, the excessive cortisol secretion leads to resistant 
hypertension, impaired glucose metabolism, dyslipidemia, and hypercoagulable state due to 
alterations of clotting factors (2) that increase the incidence of cardiovascular events and the mortality 
of untreated patients (3, 4). The impairment of cardiovascular system and glucose metabolism is often 
associated with an increased rate of severe infectious complications (5), increased incidence of 
osteoporotic fractures, and psychiatric disorders (6). Therefore, Cushing´s syndrome is a severe 
condition that must be promptly recognized, to address rapidly the patient to the best therapeutic 
option. 
 
Molecular basis of hypercortisolism and adrenocortical mass formation 
Since the first discovery of somatic activating mutations of the Gs protein in growth hormone secreting 
adenomas (7), the role of alterations of the cAMP signaling pathway in endocrine tumorigenesis and 
hyperfunction has been extensively investigated. The cAMP pathway has been shown to be one of the 
major players in the regulation of steroidogenesis in adrenocortical cells (8). Therefore, it has been 
postulated that the impairment of one or more components of this intracellular pathway could lead to 
cortisol hypersecretion and adrenocortical growth. The cAMP pathway is a ubiquitous signaling 
pathway conserved in all eukaryotes (9). In the adrenal gland, this pathway is mainly involved in the 
production of cortisol. The melanocortin 2 receptor (MC2R) is a G protein-coupled receptor widely 
expressed in cells of zona fasciculata and, to a lesser extent, zona glomerulosa. It is activated by the 
pituitary hormone ACTH, and it is involved in activation of steroidogenic processes that lead to cortisol 
production. After the binding of ACTH to its receptor, the MC2R activates the intracellular adenylate 
cyclase through its stimulatory subunit α (Gsα), leading to the generation of cAMP, as shown in Figure 
2. The increasing levels of this second messenger lead to activation of PKA, the main mediator of this 
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intracellular signaling pathway, through the binding of 
cAMP with its ligand site. PKA is a holoenzyme composed 
of four different subunits, two catalytic and two 
regulatory. Up to now, four different catalytic (Cα, Cβ, Cγ, 
and Prkx) and four regulatory (RIα, RIβ, RIIα, and RIIβ) 
subunits have been identified. The catalytic subunits are 
under the inhibitory control of the regulatory subunits. 
When cAMP binds to its receptor, the regulatory subunit 
undergoes a conformational change that allows releasing 
the catalytic subunit, which in turn phosphorylate 
cytoplasmic targets and activate the cAMP response 
element binding protein (CREB). CREB binds to the cAMP 
response elements (regulatory sequences of DNA in specific target genes) leading to the activation of 
steroidogenic transcription factors. The cAMP signaling pathway is under the regulatory control of the 
phosphodiesterases (PDEs), a group of converting enzymes that degrade the cAMP by hydrolization 
into 5´-AMP. Among the 11 PDE gene families with 100 different isoforms of proteins described in 
humans, the PDEs 2A, 8A, 8B, and 11A have been found to be expressed in the adrenal cortex (10). 
Specifically, PDE2A, PDE8B, and PDE11A have shown a predominant role in cAMP signaling regulation 
through modulation of intracellular cAMP levels stimulated by ACTH (11).  
 
Exome sequencing in sporadic adrenocortical tumors 
In the last few years, the genetic basis of Cushing´s syndrome has become clearer by the analysis of 
familial disorders associated with bilateral adrenal diseases. For instance, mutations in GNAS1 gene, 
Figure 2. Schematic representation of cAMP 
pathway. PKA: protein kinase A. C: catalytic 
subunit of PKA. R: regulatory subunit of PKA. 
CREB: cAMP response element binding 
protein. Adapted from ref. 11. 
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encoding for the Gsα subunit, in Mc-Cune Albright syndrome (12), genetic aberrations of PRKAR1A 
gene, coding for RIα subunit (13) in PPNAD in the context of Carney complex, and mutations in the 
PDE11A and PDE8B genes, encoding for PDEs, in micronodular adrenal hyperplasia (14) have 
highlighted a pivotal role of cAMP signaling pathway in the pathogenesis of hypercortisolism. Similarly, 
studies performed on sporadic adrenocortical tumors reported somatic mutations of PDE8B (15), 
PRKAR1A (16), and GNAS (17-19) in a small number of cases. The advent of next generation sequencing 
techniques has dramatically expanded our knowledge for genetic alterations in endocrine tumors. 
Examples include aldosterone producing adrenal adenomas with mutations in three groups of genes 
in approximately 50% of cases (20-22) and corticotroph pituitary adenomas with somatic USP8 
mutation in 35% of patients (23).  
Recently, somatic mutations of the gene PRKACA, which encodes the Cα subunit of PKA, were found 
in a substantial proportion of patients with Cushing’s syndrome due to sporadic adrenocortical 
adenomas (24). The most common alteration was a missense mutation (c.617A>C) leading to a single 
amino acid substitution (p.Leu206Arg). An insertion c.595_596insCAC (p.Leu199_Cys200insTrp) was 
also found in one patient. In silico and functional analysis demonstrated that those mutations generate 
an impairment of the interaction between regulatory and catalytic subunit, leading to a constitutive 
cAMP-independent activation of the latter. The functional autonomy of the Cα subunit resulted in in 
severely enhanced cortisol production, as shown by cortisol levels after dexamethasone suppression 
test, urinary free cortisol, and midnight cortisol values. The same mutation (p.Leu206Arg) has been 
also confirmed in three additional independent cohorts (17-19).  
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Research project and summary of results 
The research subject of this dissertation was focused on two main aims. The first was a characterization 
of somatic PRKACA mutations in a large cohort of sporadic adrenocortical tumors, representing the 
first replication cohort following the discovery publication. The second aim was to complete and 
extend the current knowledge on the molecular pathogenesis of adrenocortical tumors associated 
with or without cortisol secretion, by performing next generation sequencing on a large cohort of 
patients with adrenocortical tumors, without PRKACA mutations.  
To achieve these objectives, tissues were collected from several European centers in the context of 
the German Cushing Registry (CUSTODES) and the European Network for the Study of Adrenal Tumors 
(ENSAT – www.ensat.org). In 2010, a Network of Excellence for Neuroendocrine Tumors has been 
founded in Munich (NeoExNETM), with a clinical registry and associated biobank. The platform, which 
is funded as part of the m4 Cluster of Excellence (www.m4.de) has been set up to recruit patients with 
endocrine tumors, with a special focus on patients with Cushing’s syndrome. To this end, a national 
registry for patients with Cushing´s syndrome has evolved from the NeoExNET consortium, with 7 
centers being actively involved. The ENSAT has implemented a collection of adrenal tumor-related 
databases by defining a European biobank network devoted to research on adrenal tumors. Common 
standardized operational procedures (SOPs) have been developed for the collection of biological 
material from adrenal tumor patients (25) that can be subjected to integrated biomarker approaches. 
This infrastructure has been virtually linked via web-based Clinical Record Forms (eCRF) as part of the 
Research Networking Program 07-RNP-067 funded by the European Science Foundation (running 
period: July 2009 to June 2014, more information at: www.esf.org/esf-ensat). Common contentment 
forms for clinical and genetic testing have been implemented and validated in each participating 
country.  
13
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For the first part of the research project, 9 European centers were involved in the analysis of PRKACA 
mutations: Munich (Medizinische Klinik und Poliklinik IV, Klinikum der Universität München), Berlin 
(Bereich Klinische Endokrinologie, Charité Campus Mitte, Charité Universitätsmedizin), Marburg (Klinik 
für Visceral-, Thorax- und Gefäßchirurgie), Würzburg (Endocrine and Diabetes Unit, Department of 
Internal Medicine I, University Hospital, University of Würzburg), Florence (Department of 
Experimental and Clinical Biomedical Sciences), Ancona (Endocrinology Division, Department of 
Clinical and Molecular Sciences, University Hospital), Padua (Endocrinology Unit, Department of 
Medicine, University of Padua), Bologna (Endocrinology Unit, Department of Medical and Surgical 
Sciences, Alma Mater Studiorum University of Bologna), and Bordeaux (Department of Endocrinology, 
Centre Hospitalier Universitaire Bordeaux and University of Bordeaux).  
Frozen tumoral samples (n=149) and corresponding frozen normal tissue or blood (n=68) were 
collected from patients with non-secreting and cortisol-secreting adrenocortical tumors. For each 
patient, genomic DNA was extracted from frozen tissues using the Maxwell® Blood DNA Kit (Promega 
Corp., Madison, WI), according to the manufacturer´s recommendation, and amplified by polymerase 
chain reaction (PCR), with focus on exon 7, the hotspot mutation site identified in the publications 
cited above (17-19, 24). PCR products were sequenced on automated sequencer in both directions, 
performed by the facility service of Eurofins MWG Operon (Ebersberg, Germany). Patients with 
evidence of PRKACA mutations underwent PCR amplification and screening of exon 7 also in 
corresponding normal tissue or blood. The results of the sequencing were evaluated using the 
Mutation Surveyor® software (SoftGenetics, State College, PA).  
The identified somatic mutations of PRKACA were characterized by an in silico analysis, in order to 
predict the functional consequences of the genetic alterations on the respective proteins. Structural 
3D images of wild-type and mutant proteins were prepared by using the software PyMOL 
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(www.pymol.org), in collaboration with the Rudolf Virchow Center for Experimental Biomedicine, 
University of Würzburg.  
The results of this research project have confirmed and extended the important results already 
published in the first discovery study on the relevance of the somatic mutations of the Cα subunit in 
patients with Cushing´s syndrome. Indeed, we found somatic mutations of PRKACA in 34% of patients 
with Cushing´s syndrome (22/64 tumor samples). The mutations were highly specific for adrenocortical 
adenomas associated with overt cortisol hypersecretion, given that no patients with non-secreting 
tumors or subclinical hypercortisolism showed those alterations. The mutation c.617A>C 
(p.Leu206Arg) was the most frequent, occurring in 18/22 patients. However, we also identified two 
novel mutations: c.600_601insGTG - 
p.Cys200_Gly201insVal (three patients) 
and 
c.639C>G+c.638_640insATTATCCTGAGG - 
p.Ser213Arg+p.Leu212_Lys214insIle-Ile-
Leu-Arg (one tumor). In silico analysis 
predicted a pathogenetic role also for those 
two novel mutations, which are able to 
alter the interaction between the 
regulatory and the catalytic subunits of PKA 
(Figure 3).  
Moreover, patients with somatic PRKACA 
mutations showed a more severe 
hypercortisolism, as shown by higher 
cortisol levels after dexamethasone test, 
Figure 3. In silico analyses of the mutations of PRKACA. Boxes A 
to D show the structure of the mouse full-length tetrameric 
RIIβ(2):Cα(2) holoenzyme prepared using the PyMOL software 
(www.pymol.org). The RIIβ subunit of PKA is shown in green and 
the Cα subunit in red. A; Wild-type situation with Leu206 (arrow). 
B; reconstruction of the mutation p.Leu206Arg (arrow). C; the 
arrow indicates the position of the Cys200, highlighting the site 
of p.Leu199_Cys200insTrp and p.Cys200_Gly201insVal 
mutations. D; the arrow indicates the site of the 
p.Leu212_Lys214insIle Ile Leu Arg mutation.  
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and smaller adenoma diameter. Those results are in line with the concept that mutations of PKA are 
able to induce severe functional consequences in terms of steroid production and a low proliferative 
rate.  
Considering these important results, we performed a more comprehensive analysis of the genetic 
background of adrenocortical tumors by next generation sequencing, to accurately characterize the 
genetic alterations leading to tumor formation and cortisol secretion beyond PRKACA. For this second 
part of the research project, we selected tumor samples negative for mutations in exon 7 of PRKACA 
among the cohort of samples available from the aforementioned centers. In addition, samples from 
three additional centers were also included: Zagreb (Department of Endocrinology University Hospital 
Centre Zagreb, Croatia), Milan (Units of Endocrinology and Metabolic Diseases, Fondazione IRCCS Cá 
Granda-Ospedale Maggiore Policlinico, Italy), and Dresden (Departments of Clinical Chemistry and 
Laboratory Medicine, University of Dresden, Germany). A total of 99 unilateral non-secreting and 
cortisol-producing adrenocortical adenomas were enrolled. Corresponding normal tissue or blood was 
also obtained from all patients. DNA was extracted following the same procedures described above. 
After DNA quality check, exome sequencing was performed in all paired samples by the Institute of 
Human Genetics, Technische Universität München. Exomes were enriched in solution and indexed 
with the use of the SureSelect XT Human All Exon 50Mb kit, version 4 (Agilent Technologies). 
Sequencing was performed as paired-end reads of 100 bp on HiSeq2000 systems (Illumina Inc., San 
Diego, CA). Pools of 12 indexed libraries were sequenced on four lanes to an average depth of coverage 
between 88x and 160x. Image analysis and base calling was performed using Illumina Real Time 
Analysis. Reads were aligned against the human assembly hg19 (GRCh37) using Burrows-Wheeler 
Aligner (BWA v 0.5.9). By using SAMtools (v 0.1.18) and custom scripts, we analyzed single-nucleotide 
variants (SNVs) and small insertion/deletion (indel) for regions targeted by the exome enrichment kit. 
The varFilter script was applied to determine the variant quality. We set maximum read depth (-D) to 
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9999 and the minimum P-value for base quality bias (-2) to 1e-400. We used a custom script for 
marking of variants with adjacent bases of low-median base quality. Custom Perl scripts was used for 
annotating variants, including information on transcripts retrieved by UCSC Known Genes and RefSeq 
genes, variants recorded in dbSNP v.135, type of mutations, and corresponding protein amino acid 
change. We recorded all annotated variants in our in-house database. Therefore, we queried our 
database to identify variants in tumor tissue that were not present in the corresponding control tissue, 
in order to discover putative somatic variants. We filtered out variants that did not met the following 
criteria, in order to reduce false positives: variants already recorded in our database, those with quality 
<40, or variants that failed to pass one of the filters from filter scripts. Finally, we analyzed manually 
the raw data of the remaining variants, by using the Integrative Genomics Viewer (IGV) software. The 
Gene Ontology enRIchment anaLysis and visuaLizAtion tool (Gorilla) was used for identifying and 
visualizing enriched gene ontology (GO) terms in ranked lists of genes (biological process, function, and 
cell components) (26). The Gene Set Enrichment Analysis (GSEA) software was used to perform 
pathway analysis and gene family analysis. The protein-protein interactions were investigated by the 
STRING database (http://string-db.org) (27).  
The results of this second research project gave in-depth clues on the pathogenesis of adrenocortical 
tumors and steroid secretion. We identified 706 candidate somatic mutations in 88/99 patients, 
resulting in a median of 6 somatic mutations per sample (range 0-55). The predominant substitutions 
were the C:G>T:A transition (29%) and the C:G>A:T transversion (28%), consistent with most cancer 
types. A total of 23 single genes were found to be recurrent. Among them, the most frequently 
mutated genes were CTNNB1 and GNAS (n=39 and n=8, respectively). The most common alterations 
were missense mutations at CTNNB1 in a hot spot region, encoding a serine in position 45, with 
p.Ser45Pro and p.Ser45Phe occurring in 22 and 10 patients, respectively. CTNNB1 mutations occurred 
mostly in patients with non-functioning adenomas and in those associated with subclinical 
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hypercortisolism. GNAS somatic mutations were identified only in cortisol-producing adenomas, as 
expected, mutation prevalence was 8/74 (11%). Seven patients showed the known activating 
mutations in the region encoding the arginine in position 201, leading to the following aminoacid 
substitutions: p.Arg201His (n=3), p.Arg201Ser (n=2), and p.Arg201Cys (n=2). In one case of Cushing´s 
syndrome the novel mutation c.76A>C (p.Lys58Gln) was observed. The 3D structural in silico analysis 
showed that this aminoacid substitution is near the critical position 201, suggesting that it may alter 
its biological function. Moreover, mutations in PRKACA, occurring in regions outside the known hot 
spot site in exon 7 were detected in three cortisol-producing tumors. According to the 3D structural 
analysis, also those mutations were predicted to be damaging and potentially affecting the binding of 
the catalytic subunit to the regulatory subunit. Remarkably, mutations in genes encoding Ca++ channels 
were also found in a substantial proportion of patients. Among them, somatic mutations in genes 
encoding ryanodine receptors occurred in more than one patient. The in silico 3D structural analysis 
highlighted that mutations in RYR1 (p.Arg1469Gly and p.Val3218Leu) and RYR2 (p.Lys2264Asn) are 
located in the clamp regions of the cytoplasmic assembly, while the mutation in RYR3 (del4516) was 
pinpointed in the sliding helix region between transmembrane and cytoplasmic assemblies.  
Finally, we classified patients into three groups, according to the potential functional consequences of 
the most recurrent somatic mutations: subjects with mutations in genes encoding components of the 
classic Wnt-β catenin pathway (CTNNB1, APC, APC2, PCDH15, PCDHA8, PCDHB11, PCDHA10, PKP2), 
those with alterations in genes encoding components of the cAMP-PKA pathway (GNAS, PRKACA, 
PRKAR1A, CREB1, CREBBP, ADCY3, GRM3, GRM4, GRM6), and those with mutations in genes encoding 
Ca++ channels (CACNA1C, CACNA1E, CACNG8, RYR1, RYR2, RYR3, GRIA1, GRID1, GRIK2, GRIN1, GRIN3B, 
GRIP1). Mutations in components of the Wnt-β catenin pathway were mostly found in older patients, 
with endocrine inactive and larger tumors, whereas mutations in component of the cAMP/PKA 
pathway occur invariably in young patients with high endocrine activity. Those results are in line with 
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the data previously published by our group (24) and others (17-19), confirming that additional 
alterations of the PKA pathway, apart from the well-known mutations in the catalytic subunit of PKA, 
result indeed in a severe hormonal profile and, likely, in an early diagnosis. On the other side, 
alterations of components of Ca++ channels seem not to be associated with peculiar clinical or 
hormonal characteristics. Despite the well-defined role of genes involved in intracellular calcium 
homeostasis in the pathophysiology of aldosterone-producing adenomas (i.e. KCJN5, ATP1A1, ATP2B3, 
and CACNA1D) (20-22) and GH-secreting pituitary adenomas (28), the role of Ca++ channel mutations 
in non-aldosterone-secreting adenomas is not completely clear up to now. Recent data show that Ca++ 
channels could be involved in molecular mechanisms of apoptosis regulation and cancer 
transformation (29, 30), and, therefore, a role of those mutations in the proliferation of adrenocortical 
cells is conceivable.  
 
Significance and future directions 
The results of these two research projects are timely and provide novel information on the 
pathogenesis of adrenocortical adenomas. The strength of these studies relies on the high number of 
participants and on the rigorous methodology in the selection of the patients. Since the first discovery 
of alterations of GNAS mutations, the involvement of the cAMP/PKA pathway has been intensively 
studied. However, conclusions have been based on small number of patients. By the advent of highly 
accurate techniques like next generation sequencing, the power of the analysis of the genetic 
background of adrenocortical tumors has increased substantially. Here we show for the first time data 
on a follow-up study focused on PRKACA mutations (the most frequent alteration in cortisol-secreting 
adrenocortical tumors) and results of the analysis of exome sequencing in a large cohort of selected 
adrenal tissues, with precise and reliable clinical information. The future goal in the research field of 
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adrenocortical tumors is to study in detail the effects of the most relevant mutations, to identify novel 
mechanisms of tumor formation and steroid secretion, by adding the important information obtained 
by transcriptome analysis (RNA-sequencing) and metabolomic profile in tissue and blood. A second 
target for the next future is to better characterize the clinical phenotype of those patients, by 
integrating the genetic data with comprehensive steroid profiling performed by mass spectrometry, to 
be able to accurately select patients for genetic screening and targeted therapies.  
 
Notes 
In the first publications, I contributed to the research plan by collecting sample and clinical data, 
performing the genetic analysis of the whole cohort of samples and the statistical analysis, interpreting 
the results, doing literature research and writing the paper.  
In the second publication (shared first authorship), I contributed to the research project by collecting 
patient’s material (n=53/99 subjects), performing DNA extraction and quality controls, analyzing the 
results of the exome sequencing, performing statistical analysis and literature research, and writing 
the paper.  
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Summary 
Cushing's syndrome is a severe pathological condition characterized by excessive cortisol production. 
Recently, our group and others identified somatic mutations in PRKACA gene, encoding the catalytic 
subunit of protein kinase A (PKA), in a high proportion of sporadic adrenocortical adenomas associated 
with Cushing´s syndrome. The first aim of this study was to identify the prevalence of PRKACA somatic 
mutations in a comprehensive replication cohort of different adrenocortical tumors. The second aim 
was to characterize the genetic landscape underlying adrenocortical tumor formation and cortisol 
production in those cases without PRKACA recurrent mutations. 
In the first part of the study, we analyzed 149 tumor samples from several European centers by 
targeted sequencing. In the second part, 99 paired tumor/blood samples without PRKACA hot-spot 
mutations were analyzed by whole exome sequencing. Clinical and hormonal data were collected from 
the German Cushing Registry and from the databank of the European Network for the Study of Adrenal 
Tumors (ENSAT). 
Targeted sequencing identified PRKACA somatic mutations in 34% of tumors of patients with Cushing’s 
syndrome, whereas no genetic alterations were found in the remaining cases. We identified the 
PRKACA hot-spot mutation c.617A>C (p.Leu206Arg) in 18/22 patients and two novel variants of this 
gene: three tumors harbored the c.600_601insGTG variant (p.Cys200_Gly201insVal), whereas one 
patient showed the c.639C>G+c.638_640insATTATCCTGAGG variant 
(p.Ser213Arg+p.Leu212_Lys214insIle-Ile-Leu-Arg). All PRKACA mutations led to alterations of a region 
of the catalytic subunit of PKA implicated in the interaction with the regulatory subunit. Tumors with 
somatic PRKACA mutations were smaller and associated with higher levels of cortisol following 
dexamethasone suppression, compared to non-mutated tumors. 
21
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The exome sequencing of PRKACA wild-type tumors showed a median of 6 somatic protein-altering 
mutations per tumor (total n= 706), in 89% of the cases. We identified somatic mutations in genes 
encoding proteins involved in the cAMP/PKA pathway (associated with female sex and overt Cushing’s 
syndrome) and alterations in different genes involved in Ca2+-signaling and Wnt/β-catenin pathway, 
in larger endocrine inactive tumors.  
The first part of this study represents the very first follow-up analysis on genetic alterations in 
adrenocortical tumors, confirming and extending the findings of the exploratory study showing the 
prevalent role of PRKACA somatic mutations in cortisol-producing adrenocortical tumors. The second 
part of this study, which is the largest sequencing effort on adrenocortical tumors performed up to 
now, clearly shows that somatic alterations in genes of cAMP/PKA, Wnt/β-catenin, and Ca2+-signaling 
pathways are the main alterations underlying PRKACA-negative tumors, providing valuable 
information on the pathogenesis of adrenocortical tumorigenesis and cortisol-production. 
 
Zusammenfassung  
Das Cushing-Syndrom ist eine schwere Erkrankung, welche durch eine übermäßige Cortisol-Produktion 
gekennzeichnet ist. Vor kurzem identifizierte unsere Gruppe somatische Mutationen im PRKACA Gen, 
welches für die katalytische Untereinheit der Proteinkinase A (PKA) codiert. Diese Mutationen fanden 
vor allem in sporadischen Cortisol-produzierenden Nebennierenrindenadenomen mit floridem 
Cushing. Das erste Ziel dieser Studie war es, die Prävalenz von somatischen PRKACA-Mutationen in 
einer großen Serie von unterschiedlichen Nebennierenrindentumoren zu identifizieren. Das zweite Ziel 
war es, die genetischen Ereignisse, die der Nebennierenrindentumorbildung und der Produktion des 
Cortisols zugrunde liegen, in solchen Adenomen zu identifizieren, welche keine rekurrierte Hotspot-
PRKACA-Mutation aufweisen. 
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Im ersten Teil der Studie wurden 149 Tumorproben aus mehreren europäischen Zentren durch gezielte 
Sequenzierung analysiert. Im zweiten Teil wurden 99 Tumorproben mit korrespondierender normaler 
DNA nach Ausschluß von PRKACA-Hot-Spot-Mutationen mittels Exome-Sequenzierung analysiert. 
Klinische und hormonelle Daten wurden aus dem deutschen Cushing-Register und aus dem European 
Network for the Study of Adrenal Tumors (ENSAT) extrahiert und analysiert. 
Die gezielte Sequenzierung identifizierte somatische PRKACA-Mutationen bei 34% der Tumoren von 
Patienten mit floridem Cushing-Syndrom. In den verbleibenden Fällen wurden keine genetischen 
Veränderungen gefunden wurden. Wir identifizierten die PRKACA-Hot-Spot-Mutation c.617A> C 
(p.Leu206Arg) bei 18/22 Patienten und zwei neue Varianten dieses Gens: c.600_601insGTG 
(p.Cys200_Gly201insVal) bei drei Patienten und c.639C> G + c .638_640insATTATCCTGAGG 
(p.Ser213Arg + p.Leu212_Lys214insIle-Ile-Leu-Arg) bei einem Patienten. Eine In-silico-Analyse dieser 
PRKACA-Mutationen sagte Strukturveränderungen in Regionen der katalytischen Untereinheit von 
PKA vorher, die in Protein-Protein-Interaktionen mit der regulatorischen Untereinheit involviert sind. 
Patienten mit somatischen PRKACA-Mutationen zeigten höhere Cortisolwerte im Dexamethason-
Hemmtest und hatten kleinere Adenome im Vergleich zu nicht-mutierten Probanden. 
Die Exom-Sequenzierung von PRKACA-Wildtyp-Tumoren zeigten insgesamt 706 somatische Protein-
verändernde Mutationen bei 88/99 Tumoren (Median: 6 pro Tumor). Wir identifizierten mehrere 
Mutationen in den Genen des cAMP/PKA-Signalweges, die mit weiblichem Geschlecht und einem 
floriden Cushing-Syndrom assoziiert waren.  Größere endokrin inaktive Tumore wiesen Mutationen in 
Genen, die an Ca2+- Signalwegen und Wnt/β-Catenin-Signalwegen beteiligt sind, auf.  
Der erste Teil dieser Studie bestätigt und erweitert die Ergebnisse der initialen Publikation, die die 
vorherrschende Rolle der somatischen PRKACA-Mutationen bei Cortisol-produzierenden 
Nebennierenrindentumoren zeigte. Der zweite Teil dieser Studie, die bislang größte Exome-
23
Di Dalmazi - Doctoral Thesis 
 
 
Sequenzierungsbemühung bei Nebennierenrindentumoren, zeigte eindeutig, dass somatische 
Veränderungen der Gene von cAMP/PKA, Wnt/β-Catenin und Ca2+-Signalwege die wichtigsten 
Veränderungen in PRKACA-negativen Tumoren sind. Diese Studie liefert wichtige Informationen über 
die Pathogenese der Nebennierenrindentumoren und Cortisol-Produktion. 
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Context: Somatic mutations in PRKACA gene, encoding the catalytic subunit of protein kinase A
(PKA), have been recently found in a high proportion of sporadic adenomas associatedwith Cush-
ing’s syndrome. The aim was to analyze the PRKACA mutation in a large cohort of patients with
adrenocortical masses.
Methods: Samples fromnine European centerswere included (Germany, n 4; Italy, n 4; France,
n  1). Samples were drawn from 149 patients with nonsecreting adenomas (n  32  2 peritu-
moral), subclinical hypercortisolism (n  36), Cushing’s syndrome (n  64  2 peritumoral), an-
drogen-producing tumors (n 4), adrenocortical carcinomas (n 5 2 peritumoral), and primary
bilateral macronodular adrenal hyperplasias (n  8). Blood samples were available from patients
with nonsecreting adenomas (n  15), subclinical hypercortisolism (n  10), and Cushing’s syn-
drome (n  35). Clinical and hormonal data were collected. DNA amplification by PCR of exons 6
and 7 of the PRKACA gene and direct sequencing were performed.
Results: PRKACA heterozygous mutations were found in 22/64 samples of Cushing’s syndrome
patients (34%). No mutations were found in peritumoral tissue and blood samples or in other
tumors examined. The c.617AC (p.Leu206Arg) occurred in 18/22 patients. Furthermore, two
novel mutations were identified: c.600_601insGTG/p.Cys200_Gly201insVal in three patients
and c.639CGc.638_640insATTATCCTGAGG/p.Ser213Argp.Leu212_Lys214insIle-Ile-Leu-Arg) in
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one. All the mutations involved a region implicated in interaction between PKA regulatory and cat-
alytic subunits. Patients with somatic PRKACAmutations showed higher levels of cortisol after dexa-
methasone test and a smaller adenoma size, compared with nonmutated subjects.
Conclusions: These data confirm and extend previous observations that somatic PRKACA muta-
tions are specific for adrenocortical adenomas causing Cushing’s syndrome. (J Clin Endocrinol
Metab 99: E2093–E2100, 2014)
Endogenous hypercortisolism due to a unilateral adre-nocortical mass is by far the most common cause of
ACTH-independentCushing’s syndrome and this subtype
of hypercortisolism accounts for almost 30% of patients
withovertCushing’s syndrome (1).Theclinical phenotype
of patients with Cushing’s syndrome is characterized by
severe comorbidities, due to the excessive cortisol produc-
tion. The presence of resistant hypertension, type 2 dia-
betes, and vertebral osteoporotic fractures are common
features of the syndrome that are frequently found in as-
sociationwith typical catabolic signs suchas easybruising,
purple striae, and proximal muscle weakness (2). If not
adequately treated, severe and prolonged hypercortiso-
lism could lead to an increased morbidity and mortality,
mainly due to cardiovascular diseases (3, 4) and infectious
complications (5).
In the last few years, the molecular basis of ACTH-
independent Cushing’s syndrome has been elucidated in
bilateral adrenal disease in the context of familial disor-
ders. The impairment of the various components of the
cAMP pathway has been claimed to be related to adreno-
cortical growth and cortisol hypersecretion. For instance,
mutations in theGNAS1 gene, encoding for the subunit 
of the stimulatory G protein, has been shown to be the
causative factor of adrenal hyperplasia associated with
Cushing’s syndrome in Mc-Cune Albright syndrome (6).
Hypercortisolism in primary pigmented adrenocortical
disease in the context of Carney complex has been linked
to genetic aberrations of the PRKAR1A gene that lead to
an impairment of the regulatory subunit type 1A (R1) of
protein kinase A (PKA), one of the major effectors of the
cAMP signaling pathway (7). Mutations in the PDE11A
and PDE8B genes coding phosphodiesterases regulating
the degradation of intracellular cAMP, have been associ-
ated with micronodular adrenal hyperplasia and hyper-
cortisolism (8).
The analysis of molecular causes of ACTH-indepen-
dent Cushing’s syndrome has also been extended to spo-
radic adrenocortical tumors. Somatic mutations of the
PDE8B gene (9) and PRKAR1A gene (10) have been
found in patients with cortisol-producing adenomas. Ac-
tivatingGNASmutations have also been lately reported in
patients with adrenocortical adenomas associated with
Cushing’s syndrome (11, 12, 13). However, these muta-
tions were able to explain only a small number of cases of
adrenal hypercortisolism. Recently, somatic mutations of
the PRKACA gene, encoding for the catalytic subunit 
(C) of the PKA, have been identified in more than one
third of patients withCushing’s syndrome due to sporadic
adrenocortical adenomas (14). Themost common genetic
alteration found in these 22 patients was a missense mu-
tation that leads to constitutive activation of the C sub-
unit, resulting in cAMP-independent activity of the PKA
and enhanced cortisol production. Moreover, patients
with the mutation in the PRKACA gene had a more pro-
nounced cortisol hypersecretion than nonmutated sub-
jects. The same genetic alterations have been also con-
firmed in three very recent studies in a high proportion of
patients with Cushing’s syndrome associated with adre-
nocortical tumors (11, 12, 13).
The first aim of our study was to analyze somatic mu-
tations of the PRKACA gene in a large cohort of patients
with sporadic adrenocortical masses associated with
Cushing’s syndrome and different patterns of hormonal
secretion. The second aim of the study was to investigate
the hormonal and clinical phenotype of these patients.
Materials and Methods
Patient samples and clinical data
Nine European centers were involved in this project, four
from Germany, four from Italy and one from France. A total of
149 frozen tumoral samples were collected from patients with
nonsecreting adenomas (n  32), subclinical hypercortisolism
(n  36), Cushing’s syndrome (n  64), androgen-producing
tumors (n 4), adrenocortical carcinomas (n 5), and primary
bilateral macronodular adrenal hyperplasias (n  8). Normal
adrenal specimenswere also obtained from peritumoral samples
of four adenomas (two nonsecreting and two associated with
Cushing’s syndrome), two adrenocortical carcinomas, and two
macronodular adrenal hyperplasias. A total of 60 blood samples
were also collected from patients with nonsecreting adenomas
(n 15), subclinical hypercortisolism (n 10), and overt Cush-
ing’s syndrome (n  35). The diagnosis was histologically con-
firmed after surgery in all cases. None of the patients in this
cohort were reported in our previous study (14).
Clinical and hormonal data were recorded for each patient, if
available. The presence of hypertension, type 2 diabetes, dyslip-
idemia, and osteoporosis was assessed. The history of major
cardiovascular events was also recorded. The presenting symp-
toms at the time of diagnosis were investigated. The main hor-
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monal parameters analyzed were cortisol levels after dexameth-
asone suppression test (DST), midnight serum and/or salivary
cortisol, basal plasma ACTH levels, and 24-hour urinary free
cortisol. If available, normal reference ranges were recorded to
calculate the upper limit of normality. The size of the adrenal
mass was finally collected of each patient.
All patients gave written informed consent for the genetic
analysis.The studywasapprovedby the ethics committeeof each
individual institution.
Diagnostic criteria of nonsecreting adenomas,
subclinical hypercortisolism, and Cushing’s
syndrome
The diagnosis of ACTH-independent Cushing’s syndrome
was assessed in the presence of at least three biochemical hall-
marks of hypercortisolism, such as cortisol levels after DST
greater than 138 nmol/l (5 g/dl), basal plasma ACTH less than
2.2 pmol/l (10 pg/ml), elevated 24-hour urinary free cortisol, and
increased late-night serum and/or salivary cortisol. The diagno-
sis of Cushing’s syndrome was also made in case of typical cat-
abolic signs specific to overt hypercortisolism, such as proximal
muscleweakness, skin fragility, easybruising, inassociationwith
at least two impaired hormonal tests. Patients were defined as
having nonsecreting adenomas if they lacked typical clinical
signs of hypercortisolism and if they had normal hormonal tests.
In these patients, the response to DST was considered normal if
the cortisol levels decreased to less than 50 nmol/l (1.8g/dl). All
the patients who did not fit in the previous two categories were
considered as having subclinical hypercortisolism.
DNA extraction and PRKACA sequencing
Genomic DNA was extracted from frozen tissues using the
Maxwell BloodDNAKit (PromegaCorp), according to theman-
ufacturer’s recommendation. The qualitative and quantitative
evaluation of the DNA was assessed by spectrophotometry at
260 nm. The PCR was performed for amplification of exons 6
and 7, using the following primers: 5-GTTTCTGACGGCTG-
GACTG and 3-AGTCCACGGCCTTGTTGTAG. The PCR
program was as follows: 2-minutes denaturation at 95°C, eight
amplification cycles (15 s at 95°C, 15 s at 65°C, 1 C at each
cycle, and 30 s at 72°C) followed by 30 amplification cycles
(15 s at 95 C, 15 s at 58°C, and 30 s at 72°C), and 5 minutes at
72°C. PCR products were visualized on 1% agarose gel containing
ethidium bromide. The amplicons were sequenced on automated se-
quencer inbothdirections.The results of the sequencinganalysiswere
evaluated using theMutation Surveyor software (SoftGenetics).
In silico analysis of PRKACA mutations
Structural images were prepared using the PyMOL software
(www.pymol.org). The structure of the mouse full-length tetra-
meric RII(2):C (2) holoenzyme (15) (PDB entry 3TNP) was
used to display the catalytic (C) and the regulatory (RII) sub-
units of PKA.
Statistical analysis
Mean, SD, and frequencies were used as descriptive statistics.
Comparison between groups was performed using one-way
ANOVAand 2 tests, where appropriate. Intergroup differences
were assessed by simple contrasts applied to one-way ANOVA
and logistic regression. Data were analyzed by SPSS software
version 21.0.0.0 (IBM). Two-tailed P values less than .05 were
considered significant.
Results
General characteristics
The general characteristics of patients with nonsecret-
ing adenomas, subclinical hypercortisolism, and overt
Cushing’s syndrome are shown in Table 1. Patients with
Cushing’s syndrome were younger and the prevalence of
female sex was higher when compared with subjects with
nonsecreting adenomas and subclinical hypercortisolism.
The prevalence of type 2 diabetes at the time of diagnosis
was higher in patients with Cushing’s syndrome than in
thosewith nonsecreting adenomas,whereas no significant
difference was found between Cushing’s syndrome and
subclinical hypercortisolism groups. The serum cortisol
levels post-DST and at midnight, and the urinary free cor-
tisol were higher in patients with Cushing’s syndrome
compared with those with subclinical hypercortisolism
and nonsecreting adenomas.
Prevalence of the PRKACA mutations
Sequencing analysis showed mutations of exon 7 of the
PRKACAgenein22of64adenomaswithCushing’ssyndrome
(34%). No mutations were found in nonsecreting adenomas
and in samples frompatientswith subclinicalhypercortisolism,
nor in the remaining 24 tumoral samples of androgen-produc-
ing tumors, adrenocortical carcinomas, and primary bilateral
macronodular adrenal hyperplasias. In addition, nomutations
were found in normal adrenal tissue taken from peritu-
moral specimens. Eighteen of 22 adenomas associated
with Cushing’s syndrome showed the missense mutation
c.617AC (p.Leu206Arg). In addition, two novel muta-
tions were observed in four patients. The insertion
c.600_601insGTG (p.Cys200_Gly201insVal) was found
in three patients, and the missense mutation c.639CG
(p.Ser213Arg) associated with a 12 bp duplication
(c.638_640insATTATCCTGAGG,p.Leu212_Lys214insIle
Ile Leu Arg) was found in one patient. All the mutations
reported were heterozygous. No mutations were ob-
served in the peripheral DNA, available for 11 of the 22
patients with PRKACA mutation. Specifically, no mu-
tations were found in blood samples of the three pa-
tients with the p.Cys200_Gly201insVal mutation,
whereas the blood sample was not available for the pa-
tient with the p.Leu212_Lys214insIle Ile Leu Arg
mutation.
Location of the mutations in the PKA catalytic
subunit
All identifiedmutations involve regions that are located
at the interface between the catalytic and regulatory sub-
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units (Figure 1). We had previously performed an in silico
analysis of the most frequent mutation (p.Leu206Arg),
which suggested that the exchange of Leucine by a bulky
and positively charged amino acid such as Argininewould
lead to a steric hindrance with Val115 and Tyr228 in the
regulatory subunit, likely impairing holoenzyme forma-
tion and, hence, leading to constitutive PKA activation
(14). This hypothesis was supported by functional studies
of the Leu206Arg variant showing high basal PKA activ-
ity, lack of suppression by the regulatory subunit, and
absence of regulation by cAMP (14). Cys200 andGly201,
although not in direct contact to the regulatory subunit,
are located in a region of the catalytic subunit that is ori-
ented parallel to the inhibitory sequence (Figure 1). An
insertion between these two amino acids could lead to
“bulging” out of this region toward the inhibitory se-
quence and thereby also interfere with binding of the in-
hibitory loop. Similarly, Leu212 and Lys214 are located
on the surface of the protein and are positioned in a region
that adopts a “tip-like” structure, which is inserted into a
complementary cavityof the regulatory subunit (Figure1).
Insertion of several amino acids at this position, likely
leads to an increase of the size of the “tip” and its repo-
sitioning, which again could interfere with the interaction
between the regulatory and the catalytic subunit.
Clinical and hormonal phenotype in mutated vs
nonmutated patients
The clinical and hormonal phenotypes of the patients
with Cushing’s syndrome are shown in Table 2. Themean
size of the adrenal mass was smaller in patients with
PRKACAmutations, with respect to thosewithout (2.8
Table 1. General Characteristics of Patients With Nonsecreting Adenomas, Subclinical Hypercortisolism, and
Cushing’s Syndrome
Nonsecreting
(N  32)
Subclinical
Hypercortisolism
(N  36)
Cushing’s Syndrome
(N  64) P valuea
General Characteristics
Age, y 56.1  12.9
(n  31)
60.8  11.5
(n  36)
42.0  12.0b,c
(n  60)
.001
Female, n (%) 14/32 (43.8) 22/36 (61.1) 60 (93.8)b,c .001
Adenoma size, mm 3.6  1.5
(n  32)
4.0  1.2
(n  36)
3.6  1.4
(n  54)
.330
Co-morbidities
Hypertension, n (%) 13/27 (48.1) 23/31 (74.2) 35/54 (64.8) .116
Type 2 diabetes, n (%) 1/28 (3.6) 6/31 (19.4) 16/54 (29.6)d .021
Dyslipidemia, n (%) 7/28 (25.0) 10/30 (33.3) 19/54 (35.2) .636
Osteoporosis, n (%) 2/25 (8.0) 7/26 (26.9) 9/50 (18.0) .210
Cardiovascular diseases, n (%) 2/27 (7.4) 4/31 (12.9) 5/53 (9.4) .773
Hormonal parameters
Cortisol post-DST, nmol/l 30.1  7.8
(n  9)
165.6  178.6b
(n  29)
523.9  238.7b,c
(n  44)
.001
ACTH, pmol/l 5.1  5.6
(n  21)
2.6  1.5
(n  33)
1.0  0.6c,e
(n  50)
.001
Urinary free cortisol, nmol/d 262.4  164.7
(n  11)
217.1  265.4
(n  29)
1045.5  837.7b,c
(n  38)
.001
Urinary free cortisol, ULN 0.6  0.2
(n  9)
0.7  0.7
(n  26)
3.3  3.8f,g
(n  29)
.001
Midnight serum cortisol, nmol/l 141.5  62.6
(n  8)
198.5  63.2
(n  12)
495.9  136.2b,c
(n  16)
.001
Midnight serum cortisol, ULN 0.5  0.1
(n  8)
0.9  0.3b
(n  12)
2.4  1.2b,f
(n  14)
.001
DST, 1 mg dexamethasone suppression test; ULN, upper limit of normal.
Plus-minus values are means  SD Hormonal data are expressed in SI Units.
a One-way ANOVA (continuous variables), 2 test (categorical variables).
Pairwise comparison between groups (simple contrasts applied to one-way ANOVA and logistic regression):
b P  .001, reference category nonsecreting.
c P  .001, reference category subclinical hypercortisolism.
d P  .020, reference category nonsecreting.
e P  .003, reference category nonsecreting.
f P  .001, reference category nonsecreting.
g P  .001, reference category subclinical hypercortisolism.
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0.5 cm vs 4.0 1.5 cm, P .003). No difference in other
general characteristics and in the prevalence of preoper-
ative comorbidities was found between the two groups of
patients. The cortisol levels after DST were significantly
higher in subjects with PRKACAmutations than in those
without (615.1 167.2 nmol/l vs 460.8 262.4 nmol/l,
P .033),whereas theother hormonal parameters didnot
differ between groups. The prevalence of typical signs spe-
cific to Cushing’s syndrome was not different within the
two groups (data not shown).
Discussion
In this study we show that somatic mutations of the
PRKACA gene, resulting in a constitutive activation of the
C subunit of the PKA, occurred inmore than one third of
patients with adrenocortical adenomas associated with
Cushing’s syndrome. All these mutations were somatic
and specific of patients with ACTH-independent Cush-
ing’s syndrome. Of note, the sequencing analysis revealed
two novelmutations in exon 7 of thePRKACA gene never
described before.
As the first discoveryof somatic activatingmutations of
theGs protein in somatotrophic-secreting adenomas (16),
the role of alterations of the cAMP signaling pathway in
endocrine tumorigenesis and hyperfunction has been ex-
tensively investigated. PKA is a pivotal component of the
cAMP signaling cascade (17) and is involved in the regu-
lation of steroidogenesis in adrenocortical cells (18). The
constitutive activation of components of the cAMP path-
way and, in particular, of one of its major effectors, PKA,
has been related to the development of hypercortisolism
associated with bilateral hyperplasias, mainly in case of
germline mutations, and with sporadic unilateral adreno-
cortical adenomas, in case of somatic aberrations. Con-
sidering that PKA assumes a pivotal role in the regulation
of steroidogenesis, it is not surprising that adrenal tumors
carrying alterations in one of the subunits of PKA are
mostly cortisol secreting. The functional characterization
of the altered catalytic subunit  of PKA has been clearly
highlighted in our recent article (14), which showed that
somatic mutations of the C subunit occurred in more
than one third of patients with unilateral adenomas asso-
ciated with ACTH-independent Cushing’s syndrome,
who presented a more severe phenotype than patients
without the mutation. Our results are consistent with
these findings and with the report published by Goh et al
(12), given that somatic mutations in the PRKACA gene
have been found in 34% of patients with Cushing’s syn-
drome. In the series described by Cao et al (11) and Sato
et al (13), the prevalence of PRKACA gene mutations in
patients with Cushing’s syndrome was higher (65% and
52%, respectively). A feasible explanation could be that
stricter diagnostic criteria could have been applied for the
diagnosis of hypercortisolism. Nonetheless, the ethnic
background must be considered in interpreting these re-
sults, because it is possible that Asian patients could have
a higher frequency of PRKACA gene mutation. In addi-
tion, the data reported in this article confirm that the same
patients had higher cortisol levels after the DST. The ab-
sence of mutations in the peripheral DNA suggests that
these alterations occur only at a somatic level. The most
frequent genomic alteration was amissense mutation that
led to the previously described substitution of a Leucine
with an Arginine in the active-site cleft of C. In our series
of patients, we have confirmed that the Leu206Arg sub-
Figure 1. Position of PKA Variants. A and B, Structure derived from
the PKA tetramer (PDB entry 3TNP) with the catalytic subunit depicted
in green and the regulatory subunit in red. Cys200 and Gly201,
Leu206, as well as Leu212 to Lys214 are shown in stick representation.
A magnified view into the region of the three variants is shown in
panel B.
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stitution is indeed a frequent finding in patients with ad-
renal Cushing’s syndrome due to unilateral adenomas.
In our cohort, we were also able to identify two muta-
tions in the exon 7 of the PRKACA gene not described
before. All three mutations identified in this study are
located at the interface between the catalytic and the
regulatory subunit. Two of them (p.Leu206Arg,
p.Cys200_Gly201insVal) affect regions that are near the
inhibitory sequence of the regulatory subunit. The inhib-
itory sequence binds as tethered pseudosubstrate into the
active site cleft of the catalytic subunit, thus impeding the
access of other substrates and keeping PKA inactive in the
absence of cAMP. Similarly, the third mutation
(p.Leu212_Lys214insIle Ile Leu Arg) affects another re-
gion that extends as a “tip” into the regulatory subunit.
Thus, we hypothesize that all three mutations interfere
with the association between the regulatory and the cat-
alytic subunit. This hypothesis is consistent with the re-
sults obtained with the functional analysis of the
p.Leu206Arg and another mutation that we previously
identified in the same region (Leu199_Cys200insTrp).
These mutations have shown to lead to constitutive PKA
activation and to loss of the normal response to cAMP
(14).
Themutations in thePRKACA genewere foundonly in
patients with Cushing’s syndrome, whereas no genetic al-
terations were found in samples of patients with nonse-
creting adenomas and subclinical hypercortisolism, or in
other benign andmalignant tumor entities. The absence of
genetic aberrations of the PRKACA gene in nonsecreting
adenomas and androgen-producing tumors is not surpris-
ing, considering the selectivity of hormone hyperproduc-
tion caused by the activation of the PKA, as described
above.The absence of genetic aberrations of thePRKACA
gene in samples taken from adrenocortical cancer is in-
triguing. The role of the impairment of PKA in malignant
adrenocorticalmasses has not been completely elucidated.
According to previously published studies, it has beenpos-
tulated that PKA hyperactivation could be characteristic
for benign rather than malignant adrenocortical tumors,
Table 2. Clinical and Hormonal Phenotype in Patients With Cushing’s Syndrome With PRKACA Mutations Versus
Nonmutated Subjects
Cushing’s Syndrome
P valuea
No PRKACA
Mutations (N  42)
PRKACA Mutations
(N  22)
General Characteristics
Age, y 43.3  12.8
(n  39)
39.5  10.1
(n  21)
.242
Age at onset of symptoms, y 41.6  13.4
(n  30)
37.1  8.8
(n  16)
.234
Females, n (%) 39/42 (92.9) 21/22 (95.5) .683
Adenoma size, mm 4.0  1.5
(n  35)
2.8  0.5
(n  19)
.003
Co-morbidities
Hypertension, n (%) 21/34 (61.8) 14/20 (70.0) .541
Type 2 diabetes, n (%) 12/34 (35.3) 4/20 (20.0) .235
Dyslipidemia, n (%) 13/34 (38.2) 6/20 (30.0) .541
Osteoporosis, n (%) 6/31 (19.4) 3/19 (15.8) .750
Cardiovascular diseases, n (%) 4/33 (12.1) 1/20 (5.0) .390
Hormonal parameters
Cortisol post-DST, nmol/l 460.8  262.4
(n  26)
615.1  167.2
(n  18)
.033
ACTH, pmol/l 1.1  0.7
(n  32)
1.0  0.4
(n  18)
.683
Urinary free cortisol, nmol/d 1012.6  893.5
(n  26)
1116.9  733.6
(n  12)
.727
Urinary free cortisol, ULN 3.5  4.3
(n  20)
2.8  2.3
(n  9)
.650
Midnight serum cortisol, nmol/l 510.9  143.0
(n  12)
451.0  119.3
(n  4)
.465
Midnight serum cortisol, ULN 2.6  1.4
(n  10)
1.7  0.4
(n  4)
.221
DST, 1 mg dexamethasone suppression test; ULN, upper limit of normal.
Plus-minus values are means  SD.
a Oneway ANOVA (continuous variables), 2 test (categorical variables).
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as hypothesized in several reports that showed a reduced
expression of the transcription factor cAMP response el-
ement–binding protein in adrenocortical cancer (19, 20).
The development of well-differentiated adrenocortical
masseswitha limitedproliferative capacity causedbyPKA
alterations was also highlighted in the study by Bertherat
et al (10), who proposed a differential tumorigenetic
model involving the cAMPsignaling cascade,which seems
to be PKA dependent in benign adrenocortical masses and
PKA independent in adrenocortical cancer (10). It is plau-
sible that the mechanisms underlying the development of
benign and hyperfunctioning tumors observed in patients
with somatic mutations of the PRKAR1A gene described
by Bertherat et al (10) could be similar to those occurring
in patients with somatic mutations of the PRKACA gene,
although this hypothesis has yet to be demonstrated.
The absence of mutations in patients with subclinical
hypercortisolism is consistent with the previously re-
ported finding that constitutive activation of PKA leads to
profound hypersecretion of cortisol (14). Moreover, we
used strict criteria for the classification of the patientswho
allowed us to create a well-defined group of subjects with
true “overt” hypercortisolism, and a group of patients
with the so-called subclinical hypercortisolism. It is tempt-
ing to speculate that themolecularmechanismsunderlying
the subclinical hypercortisolism is different from those of
patients with ACTH-independent Cushing’s syndrome,
given that recent reports on the natural history of this
condition have shown that patients with subclinical hy-
percortisolismdonot develop the phenotypeof full-blown
Cushing’s syndrome during long-term followup, even in
case of increased cortisol production over time (21, 22).
The absence of mutations in patients with subclinical
Cushing’s syndrome has been confirmed also in the study
published byCao et al (11),whereas in the series described
by Goh et al (12) the p.Leu206Argmutation was found in
three patientswith this condition. This difference could be
most likely explained by the different diagnostic criteria
used to diagnose the subclinical hypercortisolism.
The analysis of the hormonal data of patients with
Cushing’s syndrome have shown increased levels of cor-
tisol after DST in mutated patients vs nonmutated ones.
This result confirms previous findings (14). However, we
did not find additional differences in the hormonal pa-
rameters analyzed. The lack of difference in basal plasma
ACTH levels is understandable, given that ACTH is sup-
pressed by definition in patients with ACTH-independent
Cushing’s syndrome and only small differences could ex-
ist, limitedby the sensitivityof thedifferent assaymethods.
The absenceof differences in urinary free cortisol andmid-
night cortisol is not fully consistent with the values of
cortisol after DST, but may be explained mainly by the
lack of complete hormonal data for all patients, and partly
by the sensitivity and the specificity of these tests that
could be affected, especially for urinary free cortisol, by
the different cutoffs, the methods of cortisol assays, and
the accuracy of urine collection (2, 23).
The finding of a reduced adenoma size in patients with
alterations of the PRKACA gene deserves particular con-
sideration. It has been previously demonstrated that a cor-
relation between adrenal mass size and increased number
of genetic aberrations exists (24, 25). Recently, a higher
total kinase activity due to high expression of the catalytic
subunit of PKA has been shown in smaller rather than
larger nodules of macronodular adrenal hyperplasias of
patients with ACTH-independent Cushing’s syndrome
(26). Moreover, a reduced weight of adrenal masses has
been clearly demonstrated in patients with sporadic ad-
renocortical tumors carrying somatic mutations in the
PRKAR1A gene (10). It is plausible that in our series of
patients the severity of the cortisol hypersecretion in mu-
tated patients could have led to an early diagnosis, pre-
venting the onset of additionalmutationswith higher pro-
liferative potential. This hypothesis is also supported by
studies performed in Pde8b KO mice. In this animal
model, the increased PKA activity has been associated
with an increased steroid production without an obvious
increase in the size of the adrenal glands (27), confirming
that PKA hyperactivation could lead to hypercortisolism
and low proliferative rate in adrenocortical cells.
Themain limitation of the study is the lack of complete
clinical and hormonal data in a subset of patients, which
has hampered a precise characterization of the patients’
phenotype. On the other hand, this is the largest cohort of
patientswith adrenocortical adenomaswhohave been an-
alyzed for mutations in the catalytic subunit of PKA until
now.
In conclusion, we have confirmed that somatic muta-
tions in the PRKACA gene (one previously known and
two newly described) occur in more than one third of
adrenocortical adenomas associated with Cushing’s syn-
drome. This study has strongly reinforced the hypothesis
that an aberrant cAMP pathway could indeed lead to tu-
moral mass formation and increase steroid production.
Although these mutations are associated with increased
hormonal activity and smaller size of the adrenalmass, the
clinical correlates are yet to be fully clarified. Additional
studies are also needed to complete the molecular land-
scape of unilateral adrenocortical adenomas associated
with ACTH-independent Cushing’s syndrome.
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Context: adrenocortical adenomas (ACAs) are among the most frequent human neoplasias. Ge-
netic alterations affecting the cAMP/PKA signaling pathway are common in cortisol-producing
ACAs, while activatingmutations in the gene encoding -catenin (CTNNB1) have been reported in
a subset of both benign and malignant adrenocortical tumors. However, the molecular patho-
genesis of most ACAs is still largely unclear.
Objective: aim of the study was to define the genetic landscape of sporadic unilateral ACAs.
Design and setting: next-generation whole-exome sequencing was performed on fresh-frozen
tumor samples and corresponding normal tissue samples.
Patients: 99 patients with ACAs (74 cortisol-producing and 25 endocrine inactive) negative for
p.Leu206Arg PRKACA mutation.
Main outcome measures: identification of known and/or new genetic alterations potentially in-
volved inadrenocortical tumorigenesis andautonomoushormonesecretion,genotype-phenotype
correlation.
Results: 706 somatic protein-altering mutations were detected in 88/99 tumors (median: 6 per
tumor).We identified severalmutations in genes of the cAMP/PKApathway, including three novel
mutations in PRKACA, associatedwith female sex and Cushing’s syndrome.We also found genetic
alterations in different genes involved in the Wnt/-catenin pathway, associated with larger tu-
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mors andendocrine inactivity, and, notably, inmanygenesof theCa2-signalingpathway. Finally,
by comparison of our genetic data with those available in the literature, we describe a compre-
hensive genetic landscape of unilateral ACAs.
Conclusions: This study provides the largest sequencing effort on ACAs up to now. We thereby
identified somatic alterations affecting knownandnovel pathways potentially involved in adrenal
tumorigenesis.
Adrenocortical adenomas (ACAs) are among the mostfrequent human neoplasias with a prevalence of
2%–3% in the general population. They are endocrine
inactive in 70% of cases, mostly incidentally-discovered,
or associated with autonomous cortisol or aldosterone
secretion. The genetic basis of several adrenal disorders
has been elucidated over the last years following classical
genetic approaches andutilizing next-generation sequenc-
ing techniques. In particular, the cAMP/protein kinase A
(PKA) pathway plays a central role in adrenocortical
growth and steroidogenesis. Specifically, genetic altera-
tions affecting the cAMP/PKA pathway, such as germline
or somatic mutations in genes encoding the regulatory
subunit1ofPKA(PRKAR1A), theproteinGs (GNAS),
and the phosphodiesterases 11A and 8B (PDE11A and
PDE8B) have been reported in cortisol-producing ACAs
(CPA) and bilateral micronodular adrenal hyperplasias
(1–5).
Recently, we and others have found somatic mutations
in the gene encoding the catalytic subunit  of PKA
(PRKACA) in 35%–70% of unilateral ACAs associated
with Cushing’s syndrome (6–10). These mutations trans-
late into a constitutive activation of PKA by interfering
with binding between its regulatory and catalytic subunits
(11). Activating mutations in the gene encoding -catenin
(CTNNB1) represent another important contributor of
adrenocortical growth. At variance with mutations in
PRKACA,CTNNB1mutations hadbeen reported in both
adrenocortical adenomas and carcinomas with similar
prevalence (10%–30%) (12–14), and had been most fre-
quently observed in noncortisol-secreting tumors (15).
Moreover, by using SNP array profiling, we have identi-
fied the presence of several recurrent copy number alter-
ations (CNA) in specific chromosomal regions that may
also play a role in the pathogenesis of these tumors
(16–17).
Despite these recent advances, the pathogenesis of a
large proportion of ACAs has remained elusive. In par-
ticular, despite representing the most frequent subtype,
endocrine inactive adenomas are the least thoroughly in-
vestigated, due to their infrequent surgical treatment and
thus underrepresentation in tissue based studies. There-
fore, the aim of the current study was to define the genetic
landscape of sporadic unilateral ACAs by next-generation
whole-exome sequencing (WES). In particular, we in-
tended to clarify the molecular mechanisms involved in
adrenocortical tumor development andprovide genotype-
phenotype correlation studies.
Materials and Methods
Tissue samples, patients, and clinical annotations
Fresh-frozen ACA tissues (n 99) and corresponding blood
or normal adrenal tissues were included from 11 centers belong-
ing to the European Network for the Study of Adrenocortical
Tumors (ENSAT, www.ensat.org). Only histologically con-
firmed unilateral ACAs were included (18). We selected endo-
crine inactive ACAs (EIA) and CPA without known
p.Leu206Arg PRKACA mutation (6–10). A subgroup of pa-
tients (n  42) had been included in an earlier report (8). All
patients provided written informed consent and the study was
approved by the ethics committee of each participating
institution.
Clinical and hormonal data were collected through the EN-
SAT registry (https://registry.ensat.org/). Overt Cushing’s syn-
drome (CS) and subclinical CS (SCS) were diagnosed according
to current guidelines (19) and defined as previously reported (6).
The final series consisted of 74 CPA (39 CS and 35 SCS) and 25
EIA (Table 1).
A comparative analysis was performed with data available
from previous WES studies on CPAs (n 79) (6, 7, 12, 13) and
ACC (n 176) (12, 20), and from “The Cancer Genome Atlas”
project (21,
https://tcga.data.nci.nih.gov/tcga/tcgaCancerDetails.jsp).
WES and data analysis
DNAwas extracted from fresh-frozen tissues and checked for
signs of degradation as previously described (6). Exomes were
enriched in solution and indexedwith the SureSelect XTHuman
All Exon (50Mb kit, version 5, Agilent Technologies, Santa
Clara, CA, USA) for library preparation. Sequencing was per-
formed as paired-end reads of 100 bp on HiSeq2500 systems
(Illumina, San Diego, CA, USA). Pools of 12 indexed libraries
were sequenced on four lanes to an average depth of coverage
between 82x and 170x. Image analysis and base calling were
performed with Real-Time Analysis software (Illumina). Reads
were aligned against the human assembly hg19 (GRCh37) using
the Burrows-Wheeler Aligner tool (BWA, v 0.7.5a). Moreover,
we performed single-nucleotide variant and small insertion and
deletion (indel) calling specifically for the regions targeted by the
exome enrichment kit, using SAMtools (v 0.1.19). Subsequently
the variants were filtered using the SAMtools varFilter script
using default parameters, with the exception of the maximum
read depth parameter, which we set to 9999. Variant detection
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was done as described earlier (6). In brief, to reduce false posi-
tives we filtered out variants that were already present in our
in-house database (currently 8000 exomes) or had variant qual-
ity less than 40. Raw read data of the remaining variants are then
manually investigated using the Integrative Genomics Viewer
(IGV). The frequency of each mutated allele was then evaluated
in large population genomics projects, such as theEXAC(Broad)
and the “1000 Genomes AF (allele frequency)” data set (Sup-
plemental Table 1).
The Gene Set Enrichment Analysis software (MSigDB data-
base v5.0) (22)was used to identify enriched gene ontology (GO)
terms in ranked lists of genes and to perform gene family and
pathway analysis (1330 gene sets), including the KEGG (Kyoto
Encyclopedia of Genes and Genomes) and the REACTOME
pathway (v55) databases.
In silico analysis
Somatic variants were evaluated by both Polymorphism Phe-
notyping v2 algorithm tool (PolyPhen-2) (http://genetics.bwh-
.harvard.edu/pph2) (23) and SIFT (Sorting Tolerant From In-
tolerant) algorithm (http://sift.jcvi.org/index.html) (24) to
predict the possible impact of an amino acid substitution on the
structure and function of a human protein. The variants were
classified as possibly pathogenic according to the given thresh-
olds (Supplemental Table 1). Most interesting recurrent genetic
alterationswere evaluatedby in silico analysis to predictwhether
the variants may be damaging. Structural images were prepared
with PyMOL software (www.pymol.org). The 3D structures of
the mammalian PKA holoenzyme containing catalytic subunit 
and regulatory subunit 2  (PRKACA-PRKAR2B), the stimula-
tory G-protein  subunit (GNAS, isophorm 15), and the ryan-
odine receptor RYR1 were acquired from Protein Data Bank
Table 1. Overview of general characteristics, clinical data, and number of somatic mutations in patients with
sporadic unilateral adrenocortical adenomas
All CS SCS EIA P value
General
characteristics
Number
of
patients
99 39 35 25
Age (yrs) 52.0 (40.5–61.5) 42.0 (35.0–50.5) 57.0 (49.0–67.0) 58.0 (51.0–66.0) 0.001
Sex (M/F) 29/70 4/35 12/23 13/12 0.001
Clinical
data
BMI (kg/
m2)
28.6 (24.5–32.8) 25.5 (22.8–32.2) 28.2 (25.1–31.9) 32.2 (28.1–36.5) 0.04
Tumor
diameter
(mm)
38.0 (30.0–48.0) 35.0 (30.0–45.0) 40.0 (30.0–47.0) 35.0 (24.0–52.0) 0.86
Cortisol
after
DST
(g/dL)
4.2 (2.3–15.1) 15.7 (12.4–21.2) 3.3 (2.8–7.0) 1.8 (1.3–2.3) 0.001
ACTH
(pg/mL)
5.0 (2.0–9.0) 3.9 (1.9–5.0) 5.0 (1.9–9.7) 15.2 (6.9–24.5) 0.001
UFC
ULN2
(n)
32 21 10 1 0.001
Midnight
cortisol
ULN2
(n)
13 9 4 0 0.015
Genetic
data
Total n°
of
somatic
mutations
706 353 204 149 0.54
Median
(range)
6 (0–55) 6 (0–55) 6 (0–16) 6 (0–19)
MeanSD 7.1  7.9 9.0  10.9 5.7  4.9 6.0  4.6
Data are expressed as median with interquartile range in parenthesis or frequencies (if not otherwise specified). P value was evaluated by Kruskal-
Wallis test and -square test, where appropriate. CS: Cushing´s syndrome, SCS: subclinical Cushing´s syndrome, EIA: endocrine inactive adenoma,
M: male, F: female, BMI: body mass index, DST: 1-mg dexamethasone suppression test, ULN: upper limit of normal, UFC: urinary free cortisol, SD:
standard deviation.
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(http://www.rcsb.org/pdb/, entries 3TNP, 1AZS, and 4UWA,
respectively). Aminoacid changes induced by mutations were
identified and displayed using the Chimera v1.10 Software.
Copy number alterations
We compared the results of WES in the present study with
previously published CNA data by SNP array profiling (17)
available in 14/99 patients.
Transcriptome analysis
Transcriptome analysis was performed by Affymetrix
HGU133Plus2, as previously described (25), on an independent
cohort of 41 ACAs, including 11 EIAs and 30 CPAs (20 CS and
10 SCS). Targeted next-generation sequencing (AmpliSeq de-
sign, IonTorrent sequencing) for CTNNB1 (Ser45 hotspot, ex-
ons 7 and 8), PRKACA (L206 hotspot),GNAS (R201 hotspot),
PRKACB andPRKAR1Awasperformedon37/41ACAs.Reads
were aligned using the humangenome assembly hg19 (GRCh37)
and variant calling was performed using Torrent Suite Software
(v. 4.2.1). Variants were annotated by ANNOVAR package
(March, 22nd 2015 release). Variants were visually validated by
IGV. Mutations were validated by Sanger sequencing. The mu-
tation status for CTNNB1 was not available for one ACA,
whereas the one for PRKAR1A and PRKACBwas not available
in four ACAs.
Transcriptome data were analyzed in R (https://cran.r-pro-
ject.org/). Unsupervised hierarchical clustering was performed
using hclust based on the top 1000 variable transcripts. Differ-
ential gene expression was generated with Limma (Linear Mod-
els forMicroarrayData (26))Rpackage, usingBenjamini-Hoch-
berg correction to adjust p-values. An extensive list of calcium-
signaling related genes was provided by the KEGG “Calcium
Signaling Pathway” gene list. Enrichment in these calcium genes
was sought among the differentially expressed genes, using the
Fisher exact test.
Statistical analysis
Unsupervised complete linkage clustering was performed on
the rowsandcolumnsusing theHammingdistance as a similarity
metric, to investigate interdependency among genetic altera-
tions. The Fisher’s exact or 2 tests, and Mann-Whitney U test
were used to investigate dichotomic and continuous variables,
where appropriate. Kruskal-Wallis test,
followed by Bonferroni post hoc test,
was performed for comparison among
groups for non-normally distributed
variables. Data are shown asmedian and
ranges, if not otherwise specified (NOS).
Statistical analyses were made using
GraphPad Prism (version 5.0, La Jolla,
CA, USA) and SPSS Software (version
21, SPSS Inc., Chicago, IL, USA). P val-
ues 0.05 were considered as statisti-
cally significant.
Results
Overview of genetic findings
Clinical and hormonal character-
istics together with the genetic data
of patients are provided in Table 1. We identified 706
nonsynonymous protein-altering somatic mutations in
88/99 samples. In 11 tumors no mutations were detected.
The somatic variants included 597missense, 45 nonsense,
31 frameshift, 24 direct splicing, and 9 indel alterations,
resulting in a median of 6 somatic mutations in exonic
regions per tumor (range: 0–55) (Figure 1 and Table 1).
According to the PolyPhen-2 algorithm, 203 mutations
were classified as probably damaging, 116 as possibly
damaging, 271 as benign, and 116 remained undefined.
The most frequent substitutions were the C:GT:A tran-
sition and the C:GA:T transversion (29% and 28% of
cases, respectively, Supplemental Figure 1). The complete
list of somatic mutations including all the information
about the type and localization of genetic alterations, the
frequency of the variants in different available databases
and the pathogenic classification is summarized in Sup-
plemental Table 1.
Specific genetic alterations
Recurrent somatic mutations (n  56) are shown in
Table 2. Themost frequent alterations were missense mu-
tations at CTNNB1, in a hot-spot region encoding serine
in position 45 (n 39). CTNNB1mutations occurred in
7/39 patients (18%) with CS, 19/35 subjects (54%) with
SCS, and 13/25 patients (52%) with EIA. Moreover, al-
terations in genes encoding several members of the cad-
herin superfamily were identified, but only those occur-
ring in PCDHGA6 were found in at least two samples.
GNAS somatic mutations were identified in 8/74 pa-
tients with CPAs (11%), two of them with SCS and six
with CS, but in none of the EIAs. In seven patients known
activatingmutationswere found at codon 201,whereas in
one patient with CS a novel probably damaging mutation
was observed (76AC, p.Lys58Gln). The 3D in silico
Figure 1. Total number of somatic mutations in each adrenocortical adenoma (n  99)
evaluated by next generation exome sequencing (median: 6 mutations per tumor).
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Table 2. List of the genes affected by recurrent mutations (in at least 2 samples) among 99 adrenocortical
adenomas
Gene
symbol Complete gene name Mutation
Amino acid
substitution
Pph2
(probability)
N of affected
samples
CS/SCS n
 39/35
EIA n
 25
CTNNB1 catenin  1 133TC p.Ser45Pro Possibly (0.905) 39 7/19 13
134CT p.Ser45Phe Probably (0.928) 22 3/10 9
130CG p.Pro44Ala1 Possibly (0.643) 10 0/6 4
134CG p.Ser45Cys Probably (0.950) 3 1/1 1
134CA p.Ser45Tyr Probably (0.950) 1 1/0 0
133TG p.Ser45Ala Benign (0.403) 1 0/1 0
110CT p.Ser37Phe Probably (1.000) 1 0/1 0
122CA p.Thr41Asn Possibly (0.468) 1 1/0 0
1564GA p.Ala522Thr Benign (0.098) 1 0/1 0
1602, indel 1 1/0 0
1 1/1 0
GNAS GNAS complex locus 602GA p.Arg201His Probably (1.000) 8 6/2 0
601CA p.Arg201Ser Probably (1.000) 3 2/1 0
601CT p.Arg201Cys Probably (1.000) 2 2/0 0
76AC p.Lys58Gln Probably (0.987) 2 1/1 0
1 1/0 0
PRKACA catalytic subunit  protein kinase A 589AG p.Trp197Arg Probably (0.969) 3 3/0 0
95TA p.Glu32Val Benign (0.064) 1 1 0
731 745del 1 1 0
1 1 0
COL5A1 collagen type V  1 935CA p.Pro3112Gln Benign (0.001) 3 1/0 2
2809GA p.Gly937Arg Probably (0.997) 1 1 0
3023CA p.Thr1008Lys Probably (0.995) 1 0 1
1 0 1
CEP76 centrosomal protein 76 kDa 293GA p.Thr98Ile Benign (0.001) 2 2/0 0
527CG p.Gly176Ala Benign (0.002) 1 1 0
1 1 0
LPPR3 lipid phosphate phosphatase-related protein type 3 428GT p.Ala143Asp Probably (0.994) 2 1/1 0
703GA p.Arg235Cys Benign (0.001) 1 1/0 0
1 0/1 0
REM1 RAS (RAD and GEM)-like GTP-binding 1 796CA p.Gln266Lys Benign (0.001) 2 1/1 0
700GT p.Glu234* 1 1/0 0
1 0/1 0
IAH1 isoamyl acetate-hydrolyzing esterase 1 homolog 701CG p.Ala234Gly Benign (0.019) 2 2/0 0
539GT p.Val177Leu Possibly (0.576) 1 1 0
1 1 0
NID2 nidogen 2 212CA p.Arg71Leu Benign (0.019) 2 1/1 0
893CT p.Arg298His Benign (0.001) 1 1/0 0
1 0/1 0
XIRP2 xin actin-binding repeat containing 2 8824CT p.Arg2942Cys Possibly (0.457) 2 1/1 0
5712GT p.Met1904Ile Benign (0.003) 1 1/0 0
1 0/1 0
ASH1 liter ash1 (absent, small, or homeotic)-like 6706GA p.Arg2239Trp Probably (0.999) 2 1/1 0
2902TA p.Lys968* 1 1/0 0
1 0/1 0
CYP17A1 cytochrome P450, family 17, subfamily A polypeptide 1 6CT p.Trp2* 2 1/1 0
979 981delCTT 1 1/0 0
1 0/1 0
TNFRSF13C tumor necrosis factor receptor superfamily, member 13C 91GT p.His31Asn Benign (0.001) 2 1/0 1
266AG p.Leu89Pro Probably (0.996) 1 1 0
1 0 1
DST dystonin 6112GC p.Pro2038Ala Benign (0.002) 2 0/1 1
13451AC p.Met4484Arg Possibly (0.622) 1 0/1 0
1 0/0 1
MBP myelin basic protein 488CT p.Trp163* Benign (0.006) 2 0/2 0
228GT p.Ser76Arg 1 0/1 0
1 0/1 0
SYNE2 spectrin repeat containing nuclear envelope 2 17381TA p.Met5794Lys Benign (0.001) 2 0/2 0
16534CA p.Leu5512Ile Benign (0.361) 1 0/1 0
1 0/1 0
RYR1 ryanodine receptor 1 412GT p.Val138Leu Probably (0.984) 2 0/1 1
4405CG p.Arg1469Gly Probably (0.987) 1 0/1 0
1 0/0 1
RYR3 ryanodine receptor 3 AGGG 2 0/1 1
13538 13538del 1 0/1 0
1 0/0 1
PCDHGA6 protocadherin  subfamily A6 1868CT p.Thr623Met Probably (0.957) 2 0/1 1
331GC p.Glu111Gln Possibly (0.892) 1 0/1 0
1 0/0 1
MTHFR methylene-tetrahydrofolate reductase NAD(P)H 221CA p.Arg74Leu Probably (0.997) 2 1/0 1
484AG p.Tyr162His Benign (0.027) 1 1 0
1 0 1
KMT2D lysine (K)-specific Methyltransferase 2D 16211GA p.Ser5404Phe Probably (0.997) 2 0/0 2
62GA p.Ala21Val Benign (0.196) 1 0 1
1 0 1
CADPS2 Ca2  -dependent secretion activator 2 58GA p.Arg20Cys Benign (0.064) 2 0/0 2
543 544insTA 1 0 1
1 0 1
pph2: PolyPhen-2 (Polymorphism Phenotyping v2) algorithm was used to predict the possible impact of an amino acid substitution on the structure
and function of a human protein. Results are expressed as probably damaging, possibly damaging and benign, with probability in parentheses).
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analysis showed that lysine 58 is near the critical position
201, suggesting a functional significance for p.Lys58Gln
substitution, similar to the known GNAS activating mu-
tations (Supplemental Figure 2).
Interestingly, we found three novel somatic mutations
in PRKACA in three patients with CS (p.Trp197Arg,
p.245 248.del and p.Glu32Val). Although those muta-
tions occurred outside the known hot-spot region of
PRKACA in exon 7, the 3D in silico analysis pointed to-
wards a potential pathogenic role for two of them.
p.Trp197Arg mutation is located at the interface between
the catalytic and the regulatory subunit. The exchange of
the hydrophobic tryptophan with the hydrophilic, posi-
tively charged arginine might lead to alteration in the in-
teraction between the subunits. Moreover, the
p.245 248.del affects a region of the catalytic subunit of
PKA at the interface with the regulatory subunit, likely
inducing a modification that alters the binding of the reg-
ulatory to the catalytic subunit. In contrast, the mutation
p.Glu32Val, with a hydrophilic, negatively charged glu-
tamate replaced by a hydrophobic valine, is situated out-
side the interaction region (Figure 2).
Several alterations were found in different ryanodine
receptors, and those occurring in RYR1 and RYR3 were
recurrent. The 3D in silico analysis revealed that muta-
tions in RYR1 (p.Arg1469Gly and p.Val3218Leu) and
RYR2 (p.Lys2264Asn) were located in the clamp regions
of the cytoplasmic assembly, while the mutation inRYR3
(del4516) was pinpointed in the sliding helix between
transmembrane and cytoplasmic assemblies (Supplemen-
tal Figure 3).
Finally, different potentially relevant “private” muta-
tions were detected, including alterations in genes encod-
ing ionotropic (GRIA1, GRIA2, GRID1, GRIK2,
GRIN1, GRIN3B, GRIP1) and metabotropic glutamate
receptors (GRM3,GRM4,GRM6).Moreover, amissense
mutation in ARMC5 (p.Pro866Leu) was observed in a
22-mm unilateral left adenoma associated with CS. How-
ever, no second hit at the ARMC5 gene was observed in
this tumor. Finally, a probably damaging frameshift mu-
tation (532 533insG) atTP53was detected in a 40-mm,
endocrine inactive, oncocytic adenoma.Unfortunately, no
follow-up data were available to ascertain the clinical
course of this patient during the postoperative period.
Gene enrichment and pathway analysis
The gene enrichment analysis identified 605/706
(86%) mutated genes associated with GO terms. Interest-
ingly, Ca2-signaling, collagen formation, and extracel-
lularmatrix organizationwere recognized as themost sig-
nificantly represented pathways (Supplemental Table 2).
The gene family analysis further showed that eight cyto-
kines and growth factors, 60 transcription factors, includ-
ing ATRX and MED12, 16 protein kinases, including
PRKACA, 14 oncogenes, including CREB1, CREBBP,
CTNNB1, and GNAS, and four tumor suppressor genes,
including APC and TP53 were included among the mu-
tated genes. None of themweremutated inmore than one
sample (Supplemental Table 3).
Genotype-phenotype correlation and
transcriptome analysis
No statistically significant relationship was found be-
tween the mutation frequency and clinical data (sex, age,
tumor size, and cortisol secretion pattern). We classified
patients into three groups according to the known or po-
tential biological consequences of the most frequent mu-
tations: subjects with mutations in genes encoding com-
ponents of the classicWnt/-catenin pathway (CTNNB1,
APC, APC2, PCDH15, PCDHA8, PCDHB11,
PCDHA10, PKP2), those with alterations in genes encod-
ing components of the cAMP/PKA pathway (GNAS,
PRKACA, PRKAR1A, CREB1, CREBBP, ADCY3,
GRM3, GRM4, GRM6), and those with mutations in
genes encoding components of Ca2-dependent signaling
(CACNA1C, CACNA1E, CACNG8, RYR1, RYR2,
RYR3, GRIA1, GRID1, GRIK2, GRIN1, GRIN3B,
GRIP1) (Supplemental Table 4). The results of the unsu-
pervised binary clustering analysis and the relationship
between the genetic landscape of tumors and the clinical
phenotype of the three groups of patients are shown in
Figure 3A and Supplemental Table 5. Patients with mu-
tations in genes encoding components of the Wnt/-
catenin pathway were older, had larger tumors, and car-
riedahigher total numberofmutations than thosewithout
these aberrations (P .05). In contrast, patients with mu-
tations in the genes encoding component of the cAMP/
PKA pathway were more frequently female and younger,
in comparison to subjects not carrying mutations (P 
.01). Mutations in genes encoding components of Ca2-
dependent signalingwere associatedwith ahigher number
ofmutationswhen compared to thosewithout (P .001),
whereasnodifference in clinical andhormonalparameters
was evident.
The results of the unsupervised clustering according to
the results of the transcriptome analysis are shown in Fig-
ure 3B andC. After considering the expression level, tran-
scriptome profile could clearly identify four groups and
well separated patients with CS from those with EIA and
SCS, and tumors with mutations of the cAMP/PKA path-
way from those with mutations in the Wnt/-catenin or
withoutmutations in one of those two pathways, showing
significant enrichments in calcium-related genes (Figure
3B). Surprisingly, restricting the analysis only to genes of
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theCa2 signalingpathway, the transcriptomeprofilewas
also able to clearly divide the patients in four groups. The
four clusters showeda good separation in patientswithCS
vs thosewithEIAor SCS, aswell as tumorswithmutations
in the cAMP/PKA vsWnt/-catenin pathway (Figure 3C).
Combined genetic and genomic analysis
We further analyzed current WES data in combination
with those from SNP array profiling available for a sub-
group of 14/99 ACAs (three with CS, seven with SCS, and
seven with EIA) (17). As summarized in Table 3, some
large chromosomal regions (16p13.3–13.2, 19p13.3–12,
7p22.3–22.1, 11p15.5, 20q13.3) and several genes were
affected by recurrent CN gains, including genes involved
in Wnt/-catenin (APC2 in two samples), cAMP/PKA
pathways (PRKACA, PRKR1B, AKAP8 in two samples)
orCa2-dependent signaling (CACNA1H in five samples,
CACNA1A and CACNA1B in two samples). There was
no significant difference in total number of CNA between
tumors with or without somatic mutations.
In 4/14 tumors no somatic mutations were detected by
WES. One of those (CS) showed a large amplification at
19p13.2–12 including the genes AKAP8, CACNA1A,
PDE4C and PRKACA. The second tumor (SCS) had am-
plifications at 7p22.2, which included PRKAR1B and
16p13.3. The third sample (EIA), presented a CN gain at
chr11p15.5 and several microamplifications, whereas the
last one (SCS), did not show any CNA in regions or genes
with presumed functional relevance.
Systematic review of genetic data available in
unilateral adrenocortical tumors
We compared the genetic findings of the present anal-
ysiswithWESdata available in the literature forACA (n
69 CPA) and ACC (n  176) (Sup-
plemental Table 6). The analysis of
PRKACA wild-type benign tumors
(n 94 CPA25 EIAs) showed that
mutations in genes involved in
cAMP/PKA pathway were present
only in CPA (20%of cases), whereas
alterations of genes involved inWnt/
-catenin signaling were mutated in
49% of CPA and in 76% of EIAs.
Alterations in genes involved in
Ca2-dependent signaling were
found in 14%of CPA and in 16%of
EIA.
We performed an unsupervised
clustering with all WES data avail-
able for ACAs (n  168), subdivid-
ing the mutations according to the
three groups defined above (Supple-
mentalFigure4).Wealsoperformed
a canonical pathway analysis considering all the 168ACA
samples together and subdividing them into the three
groups (49 CPA with PRKACAmutations, 94 CPA with-
outPRKACAmutations and 25EIA, Supplemental Table
7). In brief, genes involved in the “cancer pathways” were
present in all groups,while genes of the “calcium signaling
pathway”, “collagen formation” or “ECMorganization”
were not recorded among the PRKACA mutated CPAs.
Finally, we observed that 23% of somatic mutations
observed in our cohortwere previously reported in at least
one of the 176 ACC samples and 6% in at least twoACCs
(Supplemental Table 6 and Supplemental Figure 5). As
expected, mutations in CTNNB1, the most frequent al-
terations, were detected in 15% of ACC and in 25% of
ACA (34%ofPRKACAwild-type CPA and 52%of EIA).
Interestingly, mutations in different members of proto-
cadherin family were frequently observed in 13% of CPA
negative forPRKACAmutations, 24%ofEIAand15%of
ACC.
Discussion
The present study represents the most comprehensive ge-
netic characterization of unilateral ACA. In this large Eu-
ropean series we analyzed also for the first time endocrine
inactive adenomas that represent the most frequent but
less investigated type of ACAs. By restricting the investi-
gation to patients without mutations in the predominant
hot-spot region of PRKACA (p.Leu206Arg), WES anal-
ysis highlights substantial heterogeneity of the genetic
background of cortisol-producing and endocrine inactive
Figure 2. In silico analysis of the 3D structure changes of three novel somatic mutations in
PRKACA gene (589A-G, p.Trp197Arg; 95T-A, p.Glu32Val; and deletion in position 731–745,
p.245–248). a) wild type; b) the p.Trp197Arg mutation is at the interface between the catalytic
and regulatory subunit. The exchange of the hydrophobic tryptophan with the hydrophilic,
positively charged arginine leads to changes in this interaction. The p.245 248.del also affects a
region of the catalytic subunit of PKA at the interface with the regulatory subunit. The deletion
of this region probably leads to modification of the 3D structure and affects the binding of the
regulatory to the catalytic subunit. The mutation p.Glu32Val is situated outside the interaction
region between the catalytic and regulatory subunits of PKA or any other reported interaction
region of catalytic subunit of PKA.
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ACAs, and separates well those tumors from aldosterone-
producing ACA (27, 28). Overall, we identified 706 so-
matic mutations with a median of 6 per tumor. Many of
the 605mutated genes encoded components of the cAMP/
PKA, the Wnt/-catenin or, more surprisingly, the Ca2-
dependent signaling pathway.
Among genetic alterations of the cAMP/PKA pathway,
GNAS somatic mutations were the most frequent, being
associated with cortisol production, accordingly with
published data (7, 9–10). In addition to the previously
reported hot-spot mutations, a novel substitution
p.Lys58Gln was found in a patient with CSwith potential
Figure 3. A. Heat map of the most recurrent somatic mutations classified according to their known or potential biological consequences:
mutations in genes encoding components of Wnt- catenin pathway, those in genes encoding members of the cAMP/PKA pathway, and
mutations in genes involved in Ca2-signaling (n  99 samples). The relationship with the total number of somatic mutations and clinical
parameters is also shown. B and C. Transcriptome analysis of the cohort of additional 41 adenomas. The unsupervised clustering performed
according to the expression level from whole transcriptome profiling is shown in B, whereas the clustering restricted to Ca2 signaling-related
genes is shown in C. The relationship with somatic mutations and clinical parameters, as well as the heat map of under-/overexpressed genes in
the two pathways is also shown.
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functional relevance in our in silicomodel. Likewise, three
novel somatic mutations in PRKACA were detected in
three CPA associated with CS. Interestingly, in silico data
provide evidence that the p.Trp197Arg substitution and
the p.245–248deletionmaybe able to alter the interaction
between the catalytic and the regulatory subunit of PKA,
similarly towhat described for the p.Leu206Argmutation
(11). Moreover, the essential role of the phosphorylation
site Trp197 in the binding to PKA regulatory subunit was
already described in 1997 (29). In contrast, the localiza-
tion of the mutation p.Glu32Val outside known interact-
ing regions of the catalytic subunit, do not allow any spec-
ulation on the biological relevance of this substitution.
Other mutated components of the cAMP pathway in-
cluded PRKAR1A, CREB1 (cAMP responsive element
binding protein), CREBBP (CREB binding protein) and
three genes encoding metabotropic glutamate receptors
(mGluRs,GRM3,GRM4,GRM6). ThemutatedmGluRs
in our cohort belong to the group II and IIImGluRs,which
are G-protein-coupled receptors involved in regulation of
intracellular cAMP levels. Interestingly,mGluR3has been
previously suggested to be involved in the regulation of
steroidogenesis inadrenocortical tissues (30).Considering
the relationship with the clinical data, mutations in com-
ponent of the cAMP/PKA pathway occur invariably in
young patients with cortisol-secreting tumors. Those re-
sults are in line with the data previously published by our
group (6, 8) and others (7, 9–10), confirming that addi-
tional alterations of the cAMP pathway, apart from the
well-known PRKACA mutations, are associated with a
severe hormonal phenotype and, likely, early diagnosis.
Amongmutations affecting genes of theWnt/-catenin
pathway, as expected, the most common were somatic
mutations in CTNNB1 (39% of cases). They occurred
Table 3. Combined analysis between genetic data from the current exome-sequencing cohort and copy number
data from previous SNP array profiling in 14 adrenocortical adenomas (17)
ID Diagnosis Sex/Age
Tumor size
(mm)
N somatic mutations
in exons Recurrent mutations
N of coding copy number
alterations in exons
N of gained
single genes
Gained chromosomal
regions <1.000.000 bps
Samples without somatic mutations
AD90 CPA (SCS) M/53 50 0 - 13 14 -
AD91 CPA (SCS) M/37 25 0 - 2 0 7p22.3–22.2 (PRKAR1B)
16p13.3 (CACNA1H)
AD92 CPA (CS) M/55 40 0 - 5 4 19p13.2–12 (AKAP8, CACNA1A,
PDE4C, PRKACA)
AD93 EIA M/71 65 0 - 26 52 11p15.5
Samples with somatic mutations
AD30 CPA (CS) F/35 40 9 PRKACA 1 1 -
AD39 CPA (CS) F/43 28 8 GNAS 60 71 16p13.3 (AXIN1,
CACNA1H)
19p13.3 (APC2, GRIN3B)
AD26 CPA (SCS) F/29 20 6 GNAS 2 2 -
AD29 CPA (SCS) M/60 40 11 DST 11 6 -
AD31 CPA (SCS) F/52 60 13 CTNNB1 2 0 11q11.2
Y
AD32 CPA (SCS) F/35 30 7 - 328 134 -
AD33 CPA (SCS) F/73 30 2 GNAS 0 0
AD25 EIA F/59 53 8 CTNNB1, DST 5 4 9p11- (AKAP2, CACNA1B,
GRIN, GRIN3A, PRKACG)
AD34 EIA M/49 70 3 CTNNB1 152 1149 1p36.33–35.3
RYR1 1q22–23.1
3p21.31 (PRKAR2A)
3q28–29
4p16.3–16.1 (PDE6B)
5q35.2–35.3 (GRM6)
7p22.3–22.1 (PRKAR1B)
7q11.23
7q21.3–22.1
8q24.3 (GRINA)
9q32–33.2 (CACNA1B, GRIN1)
10q24.31–25.1 (CYP17A1, PDCD11)
11p15.5–15.4 (IGF2, H19)
11q13.1–13.5 (PDE2A)
14q32.2–33
16p13.3–13.2 (CACNA1H, CREBBP)
16q24.1
17p13.3–13.1
17q21.31–22 (CACNA1G)
17q25.1–25.3 (PDE6G)
19p13.3–12 (AKAP8, APC2,
CACNA1A, PDE4A, PDE4C, PRKACA)
19q12–13.41 (GRIK5, GRIN2D)
20q13.33
21q22.3
22q11.21–22
22q13.1–31 (CACNA1I)
Xp22.33
AD35 EIA F/53 43 7 CTNNB1 12 18 7p22.3–22.1 (PRKAR1B)
11p15.5 (IGF2, H9)
16p13.3 (CACNA1H)
20q13.3
In bold: recurrently gained chromosomal regions and genes (observed in more than one sample).
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more frequently in patients with SCS and EIA (54% and
52% of cases, respectively) than in those with CS (18%),
as previously reported (15). These findings may further
confirm a predominant role of CTNNB1 mutations in
early adrenocortical tumorigenesis. Among the compo-
nents of the Wnt/-catenin pathway, genes encoding for
the plakophilin (PKP2), member of the arm-repeat (ar-
madillo) gene family, the adenomatosis polyposis coli
(APC) andAPC2, and fourmembers of the protocadherin
family (PCDH15, PCDHA8, PCDHA10, PCDHB11)
were recognized. Protocadherins play a major role in cell-
cell adhesion and interfere with the  catenin signaling
proliferation pathway (31). Some members of the proto-
cadherin family have recently been recognized as candi-
date tumor suppressor genes (31), and somatic mutations
have been reported in squamous cell carcinoma, colon
adenocarcinoma and melanoma (see COSMIC, http://
cancer.sanger.ac.uk/cosmic/gene/analysis). Moreover,
protocadherins may play a role in cell-cell adhesion and
interfere with the Wnt/-catenin signaling pathway (32),
supporting the hypothesis that alterations of this Wnt/-
catenin regulatory signal may be relevant for adrenocor-
tical tumorigenesis. In this context, it is important tomen-
tion that the regulator ofWnt/-catenin pathwayZNRF3,
recently reported as one of the most frequently altered
genes in ACC (15), was not identified among mutated
genes in our ACA series. In general and similarly to what
previously reported for CTNNB1 mutations, the genetic
alterations in components of the Wnt/-catenin pathway
were mostly found in older patients with larger and inac-
tive tumors (19).
Among Ca2-dependent signaling pathways, genes en-
coding Ca2 receptors (CACNA1C and CACNA1E), ry-
anodine receptors (RyRs), ionotropic glutamate receptors
(iGluRs) and one glutamate receptor interacting protein
(GRIP1) were included. The RyRs are intracellular Ca2-
release channels found on the sarcoplasmic reticulum of
myocytes and on the endoplasmic reticulum of several
nonmuscular organs (33). There is some evidence on the
potential role of RyR alterations on adrenal function (34).
According to our in silico analysis of RYR1 and RYR2
mutations and considering that the interaction between
transmembrane and cytoplasmic domains of those recep-
tors is an important mechanism in Ca2 release modula-
tion (35), it is well conceivable that themutations found in
our cohort may be biologically relevant. Several genes re-
sponsible for regulation of intracellular Ca2 levels are
known or suspected to be involved in the pathogenesis of
endocrine tumors, such as aldosterone-producing adeno-
mas (KCJN5, ATP1A1, ATP2B3, and CACNA1D) (27,
28) andGH-secreting pituitary adenomas (36, 37). In con-
trast, the role of alterations ofCa2 signaling in the patho-
genesis of CPA is not well understood, even though it has
been demonstrated that adrenal fasciculata cells express
high levels of T-type and L-type Ca2 channels that may
regulate cortisol secretion (38). Additionally, Ca2 chan-
nels could be involved in molecular mechanisms of apo-
ptosis regulation and cancer transformation (39), leading
us to speculate on the proliferative role of this pathway in
adrenocortical cells. Interestingly, the transcriptome anal-
ysis performed on our independent cohort clearly showed
that the expression of Ca2 signaling-related genes in
ACAs not associated with primary hyperaldosteronism is
able to classify patients into meaningful clusters. In fact,
the unsupervised clustering restricted to the expression
levels of those genes, provided a good separation of pa-
tients with CS from those with SCS and EIA, and tumors
with mutations in the cAMP-PKA pathway from those
with Wnt/ catenin alterations. This finding, together
with the identification of somatic mutations in Ca2 sig-
naling genes in our study, provides indirect evidence for a
role of Ca2-related pathways in the tumorigenesis and
steroidogenesis of nonaldosterone secreting ACAs. Fur-
ther studies will be necessary to unravel the specific un-
derlying mechanisms.
Additional insights come from the combined analysis
with CNA available from a previous SNP array profiling
(17) in a well representative subgroup of present ACAs
(three CS, seven SCS, and seven EIA), including four sam-
ples without any somatic mutations, four with mutations
in theWnt/ catenin pathway, four with mutations in the
cAMP/PKA pathway and two samples without known
drivermutations.Here,weobserved amplifications in sev-
eral components of the Wnt/-catenin, cAMP/PKA or
Ca2-dependent signaling pathways. While this provides
additional evidence for amajor role in the pathogenesis of
ACA, no differences were observed between ACAwith or
without somatic mutations.
According to the results of the pathway analysis, com-
ponents of Ca2 signaling, collagen formation, and ex-
tracellular matrix organization were among the most sig-
nificantly represented. Extracellular matrices (ECM) are
secreted molecules composed of glycoproteins, collagens,
glycosaminoglycans and proteoglycans that can regulate
cell migration, differentiation, proliferation and survival
by communicating with intracellular cytoskeleton and
growth factor signals (40). Interestingly, aputative role for
ECM expression has been hypothesized in the develop-
ment of human adrenal cortex (41).Moreover, a previous
transcriptome study on ACAs identified enrichment in
genes related to ECM (42). However, we observed only
“private” mutations in ECM and collagen formation
pathways and it is unclear whether they derive from pro-
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liferative processes or might represent early events in ad-
renocortical tumorigenesis.
We also performed an unsupervised clustering consid-
ering the WES data available for all ACA together (n 
168) and separated for CPAs with or without PRKACA
mutations (n 49 and 94, respectively), providing results
similar to that obtained in our present series (Supplemen-
tal Figure 4). In addition, in this very large series, we ob-
served that most genetic alterations in the cAMP/PKA sig-
naling pathwaywere not associatedwith alterations at the
Wnt/-catenin or Ca2-dependent signaling pathway,
further confirming their major role in the pathogenesis of
CPAs.
The analysis of the genetic landscape of ACAs and
ACCs provides indirect evidence for the existence of an
adenoma-carcinoma sequence in adrenocortical tumors.
For instance, the frequent C:GT:A transitions observed
in our patients has been found to be a feature of most
cancer types (43), including ACC (12). Moreover, 6% of
somatic mutations identified in our series were previously
observed in at least two ACC samples (12, 20–21), giving
support to a potential role of early genetic alterations in a
multistep malignant transformation process. In this con-
text, recurrent mutations in the hot-spot region of CT-
NNB1, were among the most commonly observed alter-
ations in ACA and ACC. Thus, it is tempting to speculate
that an adenoma-to-carcinoma multistep progression
might occur in a subset of adrenocortical tumors bearing
CTNNB1mutations, with-catenin activatingmutations
as an early step in adrenocortical tumorigenesis. In sharp
contrast, 11/99 tumors did not show any detectable ge-
netic alteration by exome-sequencing. This finding might
be due to limitation of theWES technique or to the patho-
genesis of some ACA, which should be further evaluated
for different genetic aberrations (alterations in intronic
regions, alternative splicing, or gene fusions).
One limitation of the current study is the lack of func-
tional data so that we can only speculate on the biological
role of newly identified genetic variants. However, also
due to the large number of “private” mutations, this was
beyond the scope of this report that was focused on pro-
viding a comprehensive overviewof acquired genetic find-
ings and potential genotype/phenotype correlations.
Thus, targeted functional experiments will be required to
characterize mutations not described in the literature. In
contrast, the large samples size, including for the first time
also endocrine inactive adenomas, with detailed clinical
characterization and the integration of previousWESdata
available for cortisol-secreting adenomas and carcinomas
are relevant strengths of this collaborative project.
In summary, our study represents the largest sequenc-
ing effort on sporadic unilateral adrenocortical adenomas
and demonstrates the heterogeneity of the genetic back-
ground of ACAs without PRKACA p.Leu206Arg muta-
tion. Apart from the known somatic mutations, no other
recurrent mutation can alone explain the processes that
lead to tumor formation and hormone hypersecretion.
However, the provided landscape and the genetic altera-
tions in newly described pathways (ie, Ca2-dependent
signaling) are shedding light on the pathogenesis of adre-
nocortical tumors and are providing a solid basis for fu-
ture molecular analysis.
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